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ABSTRACT
Ohlemacher, Sarah K. Ph.D., Purdue University, August 2018. Analysis of Retinal
Ganglion Cell Development: From Stem Cells to Synapses. Major Professor: Jason
S. Meyer.
Human pluripotent stem cells (hPSCs) have the ability to self renew indefinitely
while maintaining their pluripotency, allowing for the study of virtually any human
cell type in a dish. The focus of the current study was the differentiation of hPSCs
to retinal ganglion cells (RGCs), the primary cell type affected in optic neuropathies.
hPSCs were induced to become retinal cells using a stepwise differentiation protocol
that allowed for formation of optic vesicle (OV)-like structures. Enrichment of OV-
like structures allowed for the definitive identification of RGCs. RGCs displayed the
proper temporal, spatial, and phenotypic characteristics of RGCs developing in vivo.
To test the ability of hPSC-RGCs to serve as a disease model, lines were generated
from a patient with an E50K mutation in the Optineurin gene, causative for normal-
tension primary open angle glaucoma. E50K RGCs displayed significantly higher
levels of apoptosis compared to a control lines. Apoptosis was reduced with exposure
to neuroprotective factors. Lastly, hPSC-derived RGCs were studied for their ability
to develop functional features possessed by mature in vivo RGCs. hPSC-derived
RGCs displayed a few immature functional features and as such, strategies in which
to expedite synaptogenesis using hPSC-derived astrocytes were explored. Astrocyte
and RGG co-cultures displayed expedited synaptic and functional maturation, more
closely resembling mature in vivo RGCs. Taken together, the results of this study
have important implications for the study of RGC development and by extension, the
advancement of translational therapies for optic neuropathies.
11. INTRODUCTION
Retinal ganglion cells (RGCs) play an essential role in transmitting visual informa-
tion from the eye to the brain. When this transduction pathway is perturbed, light
information gathered from the eye cannot reach the appropriate processing centers
in the brain, resulting in blindness. Degeneration of RGCs can occur in common
disease states called optic neuropathies or can undergo damage in response to certain
instances of traumatic brain injuries [1, 2]. Irrespective of the cause of degeneration,
all of these conditions are associated with the impairment and eventual loss of RGCs,
which do not possess the capacity for regeneration into adulthood. To date, no thera-
pies exist to delay or halt progression of RGC degeneration. Furthermore, by the time
a patient observes vision abnormalities, upwards of 50% of their retinal ganglion cells
have irreversibly degenerated [3,4]. This necessitates the development of strategies to
study the etiology of degeneration and develop translational therapeutic approaches.
Human pluripotent stem cells (hPSCs) encompass both human embryonic stem
cells (hESCs) and human induced pluripotent stem cells (hiPSCs). Both popula-
tions have the remarkable ability to self renew and can be differentiated into virtually
any cell type of the body [5, 6]. Human embryonic stem cells were first generated
in 1998 by isolating the inner cell mass of a human blastocyst [5]. Soon after, re-
searchers began elucidating mechanisms conferring pluripotency, which led to the
generation of hiPSCs less than a decade later [6]. Unlike hESCs, hiPSCs can be
generated from adult somatic cells by genetic reprogramming to force expression of
pluripotency genes, making them analogous to hESCs. Reprogramming allows for the
unprecedented ability to modify somatic cells whose fates were traditionally consid-
ered to be determined. Moreover, because hiPSCs can be created from patients, they
have important implications for generation of personalized medicine. Both hESCs
and hiPSCs have revolutionized our understanding of human development, can serve
2as a complement to existing animal models, and help narrow the gap in generating
translational therapies.
1.1 RGC differentiation from hPSCs
In order to efficiently derive RGCs from hPSCs, a clear understanding of retinal
development is essential because many of the same principles are translated from
in vivo development to inform in vitro systems. For instance, retinal ganglion cells
are the earliest born neural cell type in the retina, followed closely by amacrine
cells, cones and horizontal cells [7]. At later stages of retinal development, rods
are generated, followed by bipolar cells and eventually Muller glia. Similarly, when
hPSCs are directed to differentiate toward a retinal lineage, this same birth order is
recapitulated, wherein RGCs are the first cell type specified, sequentially followed by
other retinal cell types as predicted from in vivo studies [8–13].
RGCs serve as the final output of the retina by sending light information to brain
regions such as the lateral geniculate nucleus (LGN) or superior colliculus (SC) [14,15].
As such, RGCs tend to have much larger cell bodies and thicker axons compared to
other retinal neurons, both of which are needed for long distance propagation of
action potentials [16–19]. RGC axons fasciculate in the nerve fiber layer to form
the optic nerve, which relays information to multiple brain regions. hPSC-derived
RGCs have displayed similar distinct morphologies (Figure 1.1), with long neurites
and fasciculated axons [13, 20–26]. In addition, the RGC layer occupies a distinct
position in the retinal architecture, residing in the innermost retinal layer [27–29].
Remarkably, hPSCs have shown the ability to self-organize into organoid structures
that recapitulate in vivo retinal structure. RGCs reside within the inner portion of
these retinal organoids, while photoreceptors develop near the outer layers [9, 11, 13,
30].
hPSC-derived RGCs respond to neurotransmitters such as glutamate, recapitu-
lating what is observed in vivo [21]. These cells have also exhibited excitatory postsy-
3naptic potentials (EPSPs) [20], action potentials (APs) [13,20–22,25,26], spontaneous
calcium transients [26] and are sensitive to the voltage gated potassium and sodium
channel blockers TEA and TTX, respectively [13,20,22,25,26]. While these features
do not necessarily distinguish RGCs from other neuronal cell types, RGCs are the
predominant cell type within the retina that possess these features [31].
In order to distinguish RGCs from other cell types in differentiating cultures of
hPSCs, a variety of protein markers are often used to confirm the identity of these
cells (Figure 1.1). Early studies utilized TUJ1 as a common marker of RGC-like
cells [8,32]. TUJ1 is expressed by RGCs but does not confer any specificity, as many
neuronal subtypes throughout the central nervous system (CNS) also express this
marker [33, 34]. Thus, more specific markers were needed to identify RGCs from a
pluripotent source.
Perhaps the most common transcription factor used to identity RGCs has been
BRN3. BRN3 is expressed specifically by RGCs within the retina, is expressed by a
large majority of RGCs beginning shortly after RGC specification, and its expression
persists into adulthood [35–38]. However, BRN3 expression itself is not specific to
RGCs, as it is also present in subsets of somatosensory and auditory neurons [36,
37, 39, 40]. Thus, when culturing a population of hPSCs that can differentiate into
any cell type of the body, caution must be taken not to rely solely on one marker as
confirmation of identity.
A variety of additional markers can be used to identify RGCs, including Islet1,
HuC/D, and SNCG. Within the retina, these markers show some degree of specificity
for RGCs, but they are less reliable in identifying hPSC-derived RGCs because they
are expressed in other retinal cell types [41–46]. More recently, a protein called RNA
Binding Protein With Multiple Splicing (RBMPS) has been shown to specifically label
RGCs. However, the expression of RBPMS occurs later in development, complicating
efforts to identify RGCs early in hPSC differentiation [13,21,47].
To further complicate matters, ongoing research involving the identification of
RGC subtypes has shown that some subtypes do not express common markers. For in-
4stance, many intrinsically photosensitive RGCs (ipRGCs) preferentially express Brn3
alongside the photopigment Melanopsin. However, certain populations of the M1
ipRGC subtype lack expression of any BRN3 isoform [13, 48–50]. Therefore, the
combinatorial expression of genetic markers, morphological features and functional
characteristics must be used to identify a presumptive RGC.
1.2 Translational applications of hPSC-derived RGCs
Human pluripotent stem cells have revolutionized the field of human biology.
Large populations of individual cells can be differentiated and isolated to study the
cellular mechanisms that contribute to a disease state, for high throughput drug
screening, and for development of cell replacement therapies (Figure 1.2) [51,52]. Dif-
ferentiation protocols used to generate retinal cells are numerous and provide many
different methods to derive retinal neurons [8,9,12,13,20–23,26,30,53,54]. Addition-
ally, the advent of retinal organoids allows for the retina to be studied in its native
structure, more closely resembling an in vivo tissue [9, 11,30].
hPSCs serve as an effective developmental model because they allow access to
some of the earliest time points of development that would otherwise be inaccessible
to investigation. Before the advent of pluripotent stem cells, our understanding of
human retinal development was largely informed by animal models. The only option
for studying retinogenesis in humans was through the use of human fetal or post-
mortem tissue [55]. Such samples were only accessible at limited developmental time
points and could be difficult to obtain due to legal and ethical issues. Following the
emergence of hPSC technology, studies have effectively demonstrated the ability to re-
capitulate all of the major stages of human retinogenesis. This includes the primitive
eye field stage, which gives rise to the evaginating optic vesicle, eventually developing
into retinal organoids [9–11, 13, 30]. These hPSC-derived retinal organoids contain
many distinct populations of neurons which remarkably recapitulate the cellular mo-
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Fig. 1.1. Common markers of hPSC-derived retinal ganglion cells.
hPSC-derived RGCs exhibit transcriptional and morphological fea-
tures associated with in vivo RGCs. DIC imaging of retinal cultures
demonstrated RGC-like morphology with large, three-dimensional so-
mas and long neurite projections (A). hPSC-derived RGCs can be
identified by the expression of RGC-associated transcription factors
such as ISLET1 and BRN3 (B). Immunocytochemistry displayed
unique morphological features of RGCs with BRN3-positive cells ex-
tending lengthy MAP2- and TUJ1-positive neurites (C-D).
6saicism of an in vivo retina, paving the way for a more comprehensive understanding
of human retinal development.
hPSCs can be used to generate models to elucidate mechanisms of RGC disease.
Glaucoma is the most prevalent of these disorders and it is estimated that by 2020,
79.9 million people will be diagnosed with primary open angle glaucoma (POAG) [56].
Like many forms of neurodegeneration, a majority of glaucoma cases are sporadic in
nature, while a small percentage are caused by specific gene mutations. Although
it is not known what mechanisms underlie glaucomatous degeneration, elevated in-
traocular pressure (IOP) has been commonly associated with onset of the disorder.
However, in up to 50% of POAG cases, no elevated IOP is observed [3,57,58]. Thus,
work is currently ongoing to determine the precise etiology of glaucomatous degener-
ation using hPSC disease modeling.
IntroFig2.pdf
RGC degeneration in optic neuropathies may share common features, even if the
initial causes of the disorders are different. For instance, glaucomatous degeneration
involves a targeted loss of RGCs by apoptosis [4, 59, 60]. Recapitulating this mech-
anism in a dish may provide a useful platform to study all forms of glaucoma and
complement existing animal models to help narrow the gap in generating translational
therapies. Inherited disorders are of particular interest as a disease model and offer
many advantages as a model system. Genetic forms of glaucoma are caused by known
mutations within a patients genome, allowing for more straightforward connections to
be made between cellular changes and particular genotypes [51, 61]. Genetic models
are more likely to display a phenotype in a consistent and reliable manner, allow-
ing for more straightforward experimental design and analysis. hPSC-derived retinal
neurons can be studied and clearly assayed for changes at the cellular level, such as
cell death, changes in intracellular trafficking, or disturbances of the autophagy path-
way, which might inform mechanisms of degeneration in sporadic cases [13,26,54,62].
Furthermore, when modeling forms of glaucoma involving elevated intraocular pres-
sure, the complexity of modeling diurnal changes in eye pressure in a cell culture
7CRISPR Gene Editing
of Human Pluripotent 
Stem Cells
In Vitro Modeling Cell-based Therapies
Introduce Disease 
Related Mutations Patient Specic Cells
Repair Mutations
Drug Screening
Dierentiate 
Repaired Cells
Dr
ug
 Th
era
py
Cell Replacement
Disease Modeling
Fig. 1.2. Translational applications for hPSC-derived RGCs
hPSC-derived RGCs can be used for disease modeling purposes. Mu-
tations can be introduced using CRISPR/Cas9 and isogenic controls
created to control for cell line variability. These populations can be
further used for high throughput drug screening to identify poten-
tial therapeutic compounds. hPSC-derived RGCs can also be used
for developing cell replacement therapies by correcting mutations and
inserting healthy RGCs into patients.
8system can prove challenging [63–65], underscoring the need for genetic models that
do not involve exogenous stressors to induce a phenotype. Disease models allow for
development of tests for early detection in a clinical setting [61]. Early detection is
imperative because neuroprotective strategies have a greater likelihood of success than
cell replacement therapies due to the hurdles that exist when transplanting projection
neurons in vivo.
Many genetic models of glaucomatous degeneration have been developed over
the past few years [13, 26, 54]. These include mutations in TANK Binding Kinase
1 (TBK1), Optineurin (OPTN) and SIX6, all of which have been associated with
forms of POAG. These models have recapitulated the RGC specific cell death ob-
served across all forms of glaucoma and have helped uncover the role of autophagy
dysregulation as a potential mechanisms of degeneration. These papers represent the
first demonstration of disease modeling using hPSC-derived RGCs and are an im-
portant step forward in understanding disease mechanisms and identifying potential
therapeutic interventions.
hPSCs also allow for the generation of large populations of patient specific cells for
high throughput drug screening [51, 52]. This ability has many advantages, namely
that the affected human cell type can be generated for screening instead of relying
on animal models. Although animal models provide insight as to how a drug will
impact an entire organism, many therapeutics that initially show promise in animals
fail when translated to humans in a clinical setting [66, 67]. hPSCs allow for the
screening of thousands of compounds at once, which provide critical safety and tox-
icity information to inform drug development in human cells that can complement
existing animal models and help narrow the gap in generating translational therapies.
In addition, the ability to derive patient specific cells is a groundbreaking advance-
ment in personalized medicine [51, 68]. It is well established that a patients genetic
background is a contributing factor to drug efficacy. The ability to screen compounds
on a patient’s own cells could greatly optimize the process of discovering the most
9effective therapy for a particular patient. Patient-derived RGCs can also be used to
uncover neuroprotective agents that slow or even halt the progression of degeneration.
Recent work has described the ability to elucidate potential therapeutic pathways
involved in RGC degeneration and discover suitable compounds to intervene within
pathways of interest [69]. In particular, the dual leucine zipper kinase (DLK) pathway
and its downstream partner, leucine zipper kinase (LZK) pathway, were discovered
as prospective mediators of RGC cell death and were proposed as possible targets
for intervention to increase cell survival. Treatment of RGCs with Sunitinib, a FDA-
approved drug known to interfere with the DLK and LZK pathways was shown to
enhance survival of injured hPSC-RGCs in a dose dependent manner. This study
provided integral insights into RGC degeneration, particularity the role of the DLK
and LZK pathway in RGC injury and demonstrated the first use of hPSC-derived
RGCs for drug screening applications.
However, it must be noted that limitations of hPSC in vitro systems exist. Namely,
human cells differentiated in vitro lack the inherent structure of an in vivo tissue.
Moreover, even in retinal differentiation protocols which have the ability to derive
organoids that recapitulate the three dimensional organization of an in vivo retina,
other important organ systems such as the kidneys are not present. The lack of these
organs certainly plays a role in discerning the actual pharmacokinetics of drugs of
interest. As such, hPSCs should serve as a compliment to existing animal models to
fully explore drug screening in humans.
hPSCs can also be utilized for the development of cell replacement therapies. Cell
replacement approaches will be most effective in later stages of a disease where a ma-
jority of the RGC population has already degenerated and cellular rescue is no longer
an option. Ideal replacement strategies necessitate a clearly defined and easily differ-
entiated cell type which have unique and specific features to identify them in living
culture. However, as replacement neurons will have to navigate an already unhealthy
environment to connect with their proper synaptic targets in vivo, hPSC replace-
ment strategies will most likely be successful for those cell types with relatively short
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distance synaptic targets. As such, the effective replacement of projection neurons
such as RGCs faces numerous potential obstacles before these cellular replacement
approaches can be implemented.
Transplanted RGCs must first integrate into the inner plexiform layer and connect
with their pre-synaptic targets, primarily amacrine and bipolar cells. After integra-
tion, RGCs must be able to navigate through a likely unhealthy environment and
navigate up to 110mm to reach the proper synaptic targets [19]. Once this feat has
been accomplished, RGCs must make functional connections with their postsynaptic
targets in order to propagate information from the eye to the brain.
To date, many groups have explored various aspects of this puzzle. hPSC-derived
neurons have displayed some capacity to integrate into the retina [70–74]. hPSC-
derived RGCs grown in a dish exhibit some capacity to respond to environmental
growth cues and generate lengthy neurites [13, 21, 25]. In fact, hPSC-derived RGCs
plated in close proximity to ex vivo mouse tissue can preferentially target the superior
colliculus, a main RGC synaptic target in the brain, over non-preferred synaptic target
such as the olfactory bulb [25].
Lastly, work is currently underway exploring the electrophysiological capabilities
of these cells [13, 20–22, 25, 26] to determine to what extent they can recapitulate
the mature functional characteristics of in vivo RGCs. However, much more work is
needed to piece these aspects together to ensure successful cell replacement.
1.3 Conclusion
hPSC technology allows for many different interventions at varying stages of dis-
ease. hPSCs provide a window into early human development from which we might
better understand and uncover mechanisms of disease progression and neural regen-
eration. hPSC-derived RGCs allow for personalized drug discovery to rescue degen-
erating cells early in a disorder. Furthermore, cell replacement therapies at the end
stages of disorders can be explored and developed. Although still a nascent field,
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hPSC technology holds exciting promise to bring translational therapies from bench
to bedside through the unprecedented ability to study human cells in a dish. While
many protocols exist to derive retinal cells from hPSCs, the Meyer protocol is explored
in depth in the following chapters. The method used to derive RGCs from hPSCs is
described, followed by characterization of hPSC-derived RGCs for disease modeling.
Finally, the capacity of hPSC-derived RGCs to fully mature and recapitulate features
of in vivo, adult RGCs is elucidated.
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2. GENERATION OF HIGHLY ENRICHED
POPULATIONS OF OPTIC VESICLE-LIKE RETINAL
CELLS FROM HUMAN PLURIPOTENT STEM CELLS
2.1 Introduction
In recent years, several groups have described the ability to direct hPSCs to a
retinal fate [8, 11, 32, 75–78]. In order to serve as an effective in vitro model for
human retinogenesis, as well as provide a foundation for translational applications
of these cells, the stepwise differentiation of hPSCs through all of the major stages
of retinogenesis helps to ensure the proper differentiation and prospective identifica-
tion of hPSC-derived retinal progeny [10,53,79,80]. The procedure to efficiently and
reproducibly differentiate retinal cells from hPSCs is described below (Figure 2.1).
Cells are taken through a stepwise protocol to direct them toward a neural fate by
treatment with neural induction medium (NIM), then to a retinal fate by exposure
to retinal differentiation medium (RDM). Undifferentiated hPSCs are enzymatically
lifted from matrigel-coated plates and exposed to NIM in suspension. Differentiation
in suspension allows the cells to form three-dimensional aggregates. At 7 days of
differentiation, aggregates are plated and attached to 6 well plates, where a neuroep-
ithelial fate is established. Upon 16 days of differentiation, neurospheres are lifted
and maintained in RDM to establish a three-dimensional optic vesicle (OV)-like fate.
OV structures will give rise to a variety of retinal cell types, including retinal ganglion
cells, retinal pigment epithelium (RPE), as well as cone and rod photoreceptors. The
use of this protocol to generate a myriad of retinal cell types facilitates in vitro studies
of human retinogenesis [10, 30, 53], and retinal dysfunction [10, 81–84], and provides
a large population of cells to aid in drug development in addition to patient specific
therapies [76,77,85,86].
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Day 0: hPSCs 
(Figure 2.2)
Day 5: Embryoid
Bodies
Day 10: Primitive Anterior
Neuroepithelium (Figure 2.3)
Day 20: Retinal
and Forebrain
Neurospheres
(Figure 2.5)
Day 30+: Purified
Optic Vesicle-Like
Neurospheres
(Figure 2.6)
Day 60+:
Retinal Pigmented
Epithelium (Figure 2.4)
Fig. 2.1. Overview of stepwise retinal differentiation protocol.
hPSCs can be directed to differentiate by the generation of embryoid
bodies (EBs). By 7 total days of differentiation, EBs are adhered and
maintained for a total of 16 days. Neurospheres are generated and
retinal progenitor populations can be enriched by 20 days of differen-
tiation. Retinal neurospheres will yield all of the major cell types of
the neural retina within the first 70 days of differentiation. Alterna-
tively, optic vesicle-like cultures at day 16 of differentiation may be
utilized to generate retinal pigment epithelium through the mainte-
nance of adherent cultures.
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NOTE: All medium and solutions added directly to cells must be warm. It is
recommended that reagents be heated in a 37 ◦C water bath prior to use.
NOTE: All protocols below should be performed in a Class II biological culture
hood to prevent contamination of cells.
NOTE: Standard incubation temperature is 37 ◦C with 5% CO2.
2.2 Basic protocol 1: Enzymatic passaging of human pluripotent stem
cells
The following procedure can be used to maintain and passage hPSCs for long-term
use [5,6,10,53,80,87,88]. The protocol detailed below (Figure 2.1) focuses on the use
of mTeSR1 medium and matrigel to maintain hPSCs, although previous reports have
demonstrated the ability to maintain hPSCs in alternate systems such as fibroblast
feeder cells [10, 53, 80]. Cells are maintained on matrigel-coated 6-well culture plates
and are split when a confluency of approximately 70% is reached. This will aid in
preventing spontaneous differentiation of cells due to overgrowth and subsequently
ensures that an abundant amount of cells can be collected for directed differentiation.
Typically, hPSCs are expanded at a ratio of 1:6, with a single well of cells capable
of seeding an entire six well plate. A starting population of hPSCs should display
a tightly clustered and bright morphology as well as exhibit immunoreactivity to
pluripotency markers (Figure 2.2).
2.2.1 Materials
• hPSCs plated on matrigel-coated 6 well plates
• Matrigel, hESC-qualified (BD Biosciences, see Reagents and Solutions unit)
• mTeSR1 (StemCell Technologies)
• Neural Induction Medium (NIM, see Reagents and Solutions unit)
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• DMEM-F/12, 1:1 (Life Technologies)
• Dispase (Life Technologies, see Reagents and Solutions unit)
• 6-well culture plates (Falcon)
• Inverted light microscope
• T75 Flask (Falcon)
2.2.2 Passaging undifferentiated cells
1. Matrigel coat 6-well plates (1mL/well) and transfer to incubator for a minimum
of 1 hour.
2. Aspirate excess matrigel from plates then add 2 ml mTeSR1 medium to each
well and set aside until step 13.
3. Prepare two 15 mL conical tubes, one to collect undifferentiated cells to expand
and another to collect cells that will be directed to differentiate (see section
2.2.4 regarding the generation of embryoid bodies).
4. Using an inverted light microscope, mark areas of spontaneous differentiation
in wells that will be used for expansion.
5. Transfer plate to biological safety cabinet and using a 1ml pipette tip, scrape
away any cells from the marked areas of differentiation.
6. Aspirate medium from wells, add 1ml of dispase to each well and transfer to
incubator for 10 minutes.
7. Monitor the plates every few minutes thereafter to ensure the dispase is allowing
for the start of cell detachment from the culture surface. If dispase is sufficiently
warmed to 37 ◦C, this process should not take more than 15 minutes. Once a
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Fig. 2.2. Characterization of undifferentiated hPSCs.
hPSCs displayed a typical undifferentiated morphology, including
tightly packed colonies of cells and clearly defined edges (A). RT-
PCR analysis demonstrated the expression of characteristic pluripo-
tency makers in hPSCs, while lacking mesodermal, endodermal and
ectodermal markers (B). Immunocytochemistry further demonstrated
widespread expression of pluripotency-associated transcription factors
(C-E) as well as cell surface markers (F-H).
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majority of the cell clusters display curled edges, dispase should be removed
immediately by aspiration.
8. Wash each well once with 1ml DMEM/F12, ensuring that the medium is added
to the side of the well, not directly onto the cells. Doing so will ensure that
colonies are not prematurely detached from the culture surface during the wash
step.
9. Aspirate DMEM/F12 from wells and add an additional 1ml of DMEM/F12 in
each well, this time added with force directly onto the cells to detach colonies
from the plate by pipetting. Note that it is better to forcefully dislodge colonies
by pipetting 3-4 times than to gently agitate any more than this. Minimizing
the amount the cells are broken up is key to ensure maximum survival.
10. Transfer the cells from marked wells that will be expanded in one 15ml conical
tube and remaining wells for retinal differentiation to another 15ml conical tube.
2.2.3 Expansion of undifferentiated hPSCs
11. Allow cells to settle to the bottom of 15 ml conical tube (either by gravity or
centrifuge for 1 minute at 800 rpm) and aspirate supernatant, taking care to
avoid aspirating the cell pellet.
12. Re-suspend cells in mTeSR1 medium so that each new well will receive 500µL of
cell suspension per well. For example, if one well of hPSCs is being passaged to
six new wells, 3 ml of mTeSR1 should be used. Break up clusters by pipetting
forcefully 4-5 times with a 5 mL serological pipette. Note that each cell line
can vary in ease of breaking up cell clusters. If cell clusters are not broken up
sufficiently, increase pipetting during the next passage. It is better that clusters
remain large than to break them up too much.
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13. Pipet 500µL of undifferentiated cell suspension at a 90 degree angle into each
new well from step 2.
14. Transfer to the incubator and agitate plates in side-to-side followed by front-
to-back motions to ensure even distribution of cells. Be sure to pause briefly
between each series of agitations to ensure that cells are evenly dispersed across
the well rather than accumulated in the middle.
15. Medium should be changed daily (2mL/well) until the next passage, typically
within 4-5 days.
2.2.4 Generation of embryoid bodies for differentiation
16. To begin the differentiation process, cells must be slowly transitioned out of
mTeSR1 medium into NIM, and maintained in a T75 flask. Day 0 is defined as
the day cells are lifted from the Matrigel plate.
17. After cells have settled by gravity in the 15 ml conical tube (from step 10),
aspirate the supernatant. Gently resuspend the cell pellet in a 3:1 mixture
of mTeSR1:NIM and transfer to a T75 flask, and place flask in the incubator
overnight.
18. Over the first few days of differentiation, embryoid bodies should be gradually
transitioned from mTeSR1 to NIM. To accomplish this, transition cells with the
following ratios of mTeSR1 to NIM. Day 0- 3:1 Day 1- 1:1 Day 2- 1:3 Day 3-
Complete NIM
19. After day 3 of differentiation, change NIM every other day until day 7 is reached.
19
2.3 Basic protocol 2: Induction to a primitive anterior neuroepithelial
fate
As retinal cells are derived from a pluripotent source through a stepwise process
in vivo [89–92], likewise hPSCs should be differentiated through analogous stages of
differentiation, including a primitive anterior neural fate, an optic vesicle stage, and
eventually a retinal and/or RPE fate [10,30,53,80]. To initiate this stepwise process,
embryoid bodies are kept in suspension to begin differentiation for the first 7 days,
at which point they are allowed to adhere to 6-well plates and maintained until day
16. By day 10 of differentiation, cells can be characterized by a larger, more uniform
appearance as well as the expression of typical neural and eye field transcription
factors (Figure 2.3).
2.3.1 Materials
• hPSC-derived embryoid bodies in T75 flask (from Basic Protocol 1)
• NIM (see Reagents and Solutions unit)
• Fetal Bovine Serum
2.3.2 Plating embryoid bodies
After 7 total days of differentiation, cells should be plated onto 6-well culture plates
to allow for further neural differentiation. This can be accomplished by the addition
of 10% fetal bovine serum (FBS) for the first 24 hours of the plating process to ensure
cells adhere to the wells. In general, EBs derived from 5 wells of undifferentiated cells
will plate on 1 six well plate, approximately 30-40 EBs per well.
1. Collect EBs in a 15mL conical tube and allow them to settle by gravity, typically
within 5 minutes.
2. Add 2 mL of NIM to each well of a 6 well plate.
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Fig. 2.3. Induction of hPSCs to a neural progenitor fate.
After ten days of differentiation and plating (A), differentiating hPSCs
were analyzed by RT-PCR and demonstrated expression of the neu-
ral markers PAX6 and SOX1. An anterior neural, eye-field fate was
further indicated by the expression of OTX2. RAX, SIX3, and LHX2
(B). Immunocytochemistry demonstrated the widespread expression
of many of these transcription factors (C-E).
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3. Aspirate the supernatant from the EBs, being careful to avoid removing the cell
pellet. Resuspsend the EBs in NIM so that each well will receive 200µL of the
cell suspension, and add cells to 6-well plate(s) accordingly. For one plate, cells
would be resuspended in 1.2ml of NIM.
4. Add 250 µL ( 10%) FBS to each well to allow for cell attachment to the culture
plate.
5. Transfer plates to the incubator, agitating plates in a side-to-side and then
front-to-back manner to ensure an even distribution of cells within each well.
6. The following day, aspirate medium containing FBS and add fresh NIM to each
well (2mL/well) without FBS.
7. Medium should be changed every other day until day 16 of differentiation is
reached, by which point these cells will have acquired a primitive anterior neu-
roepithelial fate.
2.4 Basic protocol 3: Differentiation of primitive anterior neuroepithelial
cells to a retinal pigment epithelial fate
During normal development, the RPE is the first retinal cell type to be specified
from a more primitive source. The RPE layer develops in a manner that is distinctly
separate from the neural retinal populations of cells, and is known to be specified in
the absence of factors instrumental in directing a neural retinal fate [93–95]. Likewise,
RPE cells generated from hPSCs are also found to differentiate through a similar
process in which RPE cells are often found in close proximity to, although distinctly
separate from, neural retinal populations [30, 96]. hPSC-derived RPE cells can be
readily identified by their accumulation of pigmentation and their distinct hexagonal
morphology (Figure 2.4), and have been successfully generated by many groups in
recent years [10,53,75,76,80,96–102].
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Fig. 2.4. Differentiation of hPSCs to retinal pigment epithelium.
hPSC-derived RPE-like cells expressed typical RPE associated mark-
ers when screened by RT-PCR (A). Under brightfield microscopy,
these cells displayed proper morphological features distinct to RPE,
including a hexagonal shape and areas of pigmentation (B).
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2.4.1 Materials
• hPSC-derived neuroepithelial cells plated on 6-well plates (from Basic Protocol
2
• Retinal Differentiation Medium (see Reagents and Solutions unit)
• poly D-ornithine/Laminin-coated coverslips in a 4 or 24 well plate (see Support
Protocol 2.7.1)
• Inverted light microscope
• FGF2 (working concentration of 20 ng/ml)
• EGF (working concentration of 20 ng/ml)
• Heparin (working concentration of 2 µg/ml)
2.4.2 Differentiation of hPSCs to retinal pigment epithelium.
hPSC-derived primitive anterior neuroepithelial cells on 6-well plates can also be
used to generate a highly pure population of RPE, characterized by a cobblestone-like
morphology as well as dark pigmentation. Continued growth and differentiation of
these cells should be maintained until an RPE morphology emerges, typically within
the first 60 days of differentiation.
1. Once day 16 of differentiation is reached, medium should be switched from
NIM to RDM and medium should be changed every 2-3 days until distinct
populations of RPE cells are readily observed, typically within 60 total days of
differentiation.
2. At day 60 of differentiation, RPE can be microdissected and isolated. To mi-
crodissect RPE, identify an area of RPE cells of suitable purity by pigmentation
and morphology under the microscope.
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3. Using a pointed object (e.g. tungsten needle, pipette tip, etc), gently scratch
away an area around the region of cells to be microdissected, freeing up the
RPE cells.
4. Using a P100 pipette, transfer this cluster of freed RPE cells with 50µL of
medium to a laminin/poly-D-ornithine-coated coverslip in a 4 or 24 well plate,
and repeat this process for as many coverslips as needed (see support protocols
for coating coverslips). Typically, one cluster of RPE cells should be sufficient
per coverslip.
5. Transfer the plate to incubator and allow RPE to attach to coverslip overnight.
6. The next day, RPE cell clusters should have adhered to the coverslips. Add
500µL of RDM supplemented with EGF (20 ng/ml), FGF2 (20 ng/ml), and
heparin to allow for proliferation of RPE cells. Replace medium and growth
factors every 2 days.
7. Within 7-10 days, RPE cells should have lost most pigmentation and their
hexagonal shape, and will have occupied most of the coverslip.
8. To allow for maturation and reacquisition of RPE morphology, remove medium
containing EGF, FGF2, and heparin and replace with RDM. Maintain in this
state for 2-3 weeks, or until a desired stage of RPE maturation is reached.
2.5 Basic protocol 4: Differentiation and long-term maintenance of reti-
nal progenitor cells
During in vivo development, after cells have adopted a primitive anterior neural
phenotype, a subset of cells are known to acquire a retinal fate and are characterized
by numerous retinal-associated features that distinguish these cells from other neural
lineages [103–106]. Once this retinal identity has been established, all mature retinal
cell types (cones, rods, retinal ganglion cells, etc.) will eventually arise. Likewise,
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hPSCs can acquire a retinal progenitor fate (Figure 2.5), eventually yielding all of
the major cell types of the retina [10, 53, 80, 96, 107]. To accomplish this differenti-
ation event, cells are lifted and maintained in floating suspension with RDM after
approximately 16 days total days of differentiation. Retinal and non-retinal cells can
then be manually separated and maintained until the desired stage of differentiation
is reached.
2.5.1 Materials
• Primitive neuroepithelial cells maintained in 6 well plates (from Basic Protocol
2)
• Retinal Differentiation Medium (see Reagents and Solutions unit)
• 60mm x 15mm polystyrene petri dishes
• 6 well plates (Falcon)
2.5.2 Generation of neurospheres from primitive anterior neuroepithelial
cells
At day 16 of differentiation, cells should be lifted from culture plates to allow for
the development of a three-dimensional OV-like structures.
1. Using a P1000 pipetman, draw up 1 ml of medium from a well of cells and
dislodge the center of each aggregate from the plate by vigorously pipetting the
medium directly at the center of each aggregate. The center of each aggregate
will dislodge, leaving behind a ring of peripheral cells possessing a flattened
appearance. It is better to pipette forcefully 5-6 times instead of gently pipetting
any more than this, as excessive pipetting results in cell death and reduced yield
of neurospheres.
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2. After dislodging the cells from the plates, transfer aggregates to a 15ml conical
tube. Allow the cell aggregates to settle by gravity or by centrifugation for 1
minute at 800rpm.
3. Aspirate the supernatant and resuspend the cells in 5ml of RDM.
4. Transfer the cell suspension to a 60mm dish and return cells to the incubator.
Cells at this stage should have their medium changed every 2-3 days.
2.5.3 Manual enrichment of retinal neurospheres
5. By day 20-25 of differentiation, two populations of neurospheres will begin to
emerge from the primitive anterior neuroepithelial cells - those possessing a
golden ring around the outside (retinal neurospheres) and those with a darker
appearance lacking this golden ring (non-retinal forebrain neurospheres). These
morphological differences can easily be observed with an inverted microscope
under a 4x objective. By 30 total days of differentiation, distinct transcriptional
profiles emerge that distinguish these two populations (Figure 2.5).
6. Enrichment of retinal neurospheres should be performed by day 25 of differ-
entiation. While viewing the cells under an inverted light microscope with a
4x objective, swirl the plate gently in a circular motion to collect cells in the
middle of the dish.
7. Looking at the neurospheres through the microscope, gently gather retinal neu-
rospheres based on their bright outer ring appearance using a P20 pipetman
and transfer these neurospheres to a 15ml conical tube containing 5ml of RDM.
Repeat until all retinal neurospheres have been collected in the same 15 ml
conical tube.
8. After collecting retinal neurospheres, transfer this population along with the
medium to a 60mm dish and return cells to the incubator. Non-retinal neu-
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rospheres may be similarly maintained for neuronal cultures if desired, or dis-
carded at this stage.
2.5.4 Maintenance of retinal neurospheres
9. From this point forward, medium will need to be replaced every other day until
the desired stage of retinal differentiation is reached.
10. Tilt the plate towards you to allow the medium and neurospheres to collect on
the bottom half of the plate.
11. Using a P1000 pipetman, transfer 1 ml of medium containing as many neuro-
spheres as possible to a 15ml conical tube while still maintaining the tilt of the
plate.
12. Collect the remaining medium and rinse over the entire surface of the plate to
collect any remaining neurospheres that may remain in the plate.
13. Transfer this remaining medium to the 15ml conical tube.
14. Allow neurospheres to settle to the bottom of the tube and then aspirate the
supernatant.
15. Resuspend neurospheres in 5ml of fresh RDM and transfer this cell suspension
back to the dish. The dish should be stored in the incubator for further use.
2.6 Basic protocol 5: Induction of retinal progenitors to specific retinal
subtypes
Previous studies have demonstrated the ability to yield all of the major classes
of retinal cells from hPSC-derived retinal progenitor cells, including photorecep-
tors [10, 30, 32, 53, 77, 78, 108] and retinal ganglion cells [10, 30, 77, 80]. In order to
derive these various types of retinal cells, retinal neurospheres must be maintained in
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differentiating cultures for extended periods of time. Within 90 days of total differ-
entiation, neural retinal cell types including photoreceptors and retinal ganglion cells
can be identified (Figure 2.6). In order to analyze cells by immunocytochemistry, neu-
rospheres should be dissociated with accutase and then plated onto poly-D-ornithine
and laminin-coated coverslips (See Support Protocol 2.7.1 for coating coverslips). At
this point, cells demonstrate the presence of a wide variety of retinal specific tran-
scription factors and distinct neuroretinal morphologies such as neurite outgrowth
and/or axonal/dendritic arborization typical of retinal ganglion cell or photorecep-
tors (Figure 2.6).
2.6.1 Materials
• Retinal Neurospheres at 40 days total differentiation (from Basic protocol 4)
• Retinal Differentiation Medium (see Reagents and Solutions unit)
• Poly-D-ornithine and laminin-coated coverslips (see Support protocols)
• Accutase (BD Biosciences)
• Inverted light microscope
2.6.2 Dissociation and plating of retinal neurospheres
1. Place the plate of retinal neurospheres in suspension under a microscope and
swirl in a circular motion to gather cells towards the center of the field of view.
2. Gather neurospheres that will be used for dissociation and plating in a 1.5mL
tube. Note: For plating coverslips, 2-3 neurospheres/coverslip typically provide
enough density for sufficient plating and microscopy.
3. Allow neurospheres to settle at the bottom and gently remove excess medium
with a pipette.
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Fig. 2.5. Identification, enrichment, and characterization of retinal
progenitor cells.
After 30 days of differentiation, hPSCs were isolated into two mor-
phologically distinct populations (A). Retinal neurospheres were char-
acterized by a bright ring (B) and a non-retinal neural population
displayed a more uniform appearance (C). RT-PCR analysis revealed
that both populations expressed neural associated transcription fac-
tors. Retinal neurospheres exhibited markers of retinal progenitors
while the non-retinal neural cells expressed forebrain-associated tran-
scription factors (D). Retinal neurospheres widely expressed reti-
nal progenitor markers (E), but largely lacked the expression of the
forebrain-associated marker SOX1 (F). hPSC-derived retinal progen-
itors remained highly proliferative (G). Non-retinal neural popula-
tions displayed typical features of emerging forebrain neurons (H) but
lacked the retinal progenitor marker CHX10 (I). Non-retinal neural
cells retained the expression of both PAX6 and SOX1 (J).
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4. Add 100 µL of accutase.
5. Transfer to 37 ◦C water bath for 10 minutes.
6. Every 10 minutes, remove tube from water bath and forcefully agitate cells
about 4 or 5 times with a P100 (50 µL setting) pipetman to break up the cells.
7. Repeat steps 5 and 6 if clusters need further dissociation.
8. Once retinal neurospheres have been dissociated to aggregates of a desired size,
centrifuge cell suspension for 1 minute at 800 rpm. Viability is greatly increased
if cells are dissociated to yield small aggregrates of cells rather than a single cell
suspension.
9. Gently remove supernatant with a pipet and resuspend in enough RDM to
ensure each coverslip receives 50µL of cell suspension.
10. Pipet 50µL of cell suspension onto each poly-D-ornithine and laminin-coated
coverslip (see support protocol 2.7.1).
11. Transfer to incubator and allow cells to adhere overnight.
12. If cells are to be maintained on coverslips for further differentiation, add 500µL
of RDM the following day and every other day thereafter until the desired stage
of differentiation is reached. If cells are to be fixed immediately for immunocy-
tochemistry, no additional medium should be added.
2.7 Support protocols
2.7.1 Coating coverslips with poly-D-ornithine and laminin
This brief protocol will explain how to coat the coverslips for use in Basic Protocols
3 and 5. While the poly-D-ornithine increases adhesion of cells to the coverslip,
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the laminin promotes cell growth. Cells grown on poly-D-ornithine and laminin-
coated coverslips can easily be utilized for immunocytochemical analysis and readily
transferred to slides for visualization by microscopy.
2.7.2 Materials
• 24- and/or 4-well plates
• EtOH washed and subsequently autoclaved glass coverslips (12 mm)
• Stock of poly-D-ornithine (see Reagents and Solutions)
1. Transfer one coverslip to each well and ensure it lies flat on the bottom of the
well.
2. Pipet 100 µL poly-D-ornithine into the center of each coverslip. Let sit at
room temperature for 30 minutes, ensuring the poly-D-ornithine remains on
the coverslip.
3. Remove poly-D-ornithine and wash each well with 1mL of sterile water. Repeat
two more times.
4. After removing the third wash, check coverslips under microscope to make sure
any precipitate is washed away. Continue rinsing if any residue remains.
5. Remove last wash and allow coverslips to air dry in the biological safety cabinet
overnight. Be sure to leave the hood fan on and the sash slightly open.
6. The following day, remove dry coverslips from hood and store at room temper-
ature for future use.
2.7.3 Laminin-coating of coverslips
1. Add 50 µL of laminin (20 µg/ml in DMEM) directly to the center of each
coverslip previously coated with poly-D-ornithine.
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2. Transfer plates to the incubator and let stand for at least 4 hours or overnight.
3. After incubation to allow for thorough coating of coverslips with laminin, aspi-
rate excess laminin just before addition of cell suspension.
2.8 Reagents and solutions
All solutions should be made in a biological safety cabinet and filtered through a
steriflip or bottle top filter to ensure solutions are sterile.
2.8.1 Dispase
• warm DMEM F/12
• 2mg/mL dispase powder.
Combine reagents and filter. Store up to 2 weeks at 4 ◦C
2.8.2 NIM (Neural Induction Medium)
• 489.5mL DMEMF/12
• 5mL N2 supplement
• 5mL MEM NEAA
• 0.5mL Heparin (2 mg/ml)
Combine reagents and filter. Store up to 1 month at 4 ◦C
2.8.3 RDM (Retinal Differentiation Medium)
• 240mL DMEMF/12
• 240mL DMEM
33
• 10mL B27 Supplement
• 5mL MEM Non-essential amino acids
• 5mL antibiotics
Combine reagents and filter. Store up to 1 month at 4 ◦C
2.8.4 Laminin
Staring with a 1mg/mL stock, dilute laminin 1:50 in cold DMEM to a final con-
centration of 20µg/mL. Store up to 1 month at 4 ◦C.
2.8.5 Matrigel
Dilute according to the manufacturers specifications in cold DMEM.
2.8.6 Poly-D-ornithine
• poly-D-ornithine (10mg Sigma)
• Sterile H20
• 250 mL autoclaved beaker
• 50 mL conical tubes
• Steriflip 0.2 mm filtering device
1. Tap the bottle of poly-D-ornithine on the surface of the hood and open carefully
as to not lose any powder.
2. Slowly pipet 1mL of sterile water into the bottle, put the top back on, and shake
vigorously. Remove cap carefully and transfer to the beaker.
3. Repeat process about 4 more times to remove trace amounts from the bottle.
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4. To the beaker, add sterile water up to a volume of 100mL. Pipet up and down
to mix thoroughly.
5. Transfer 50mL into each conical tube. Sterile filter each using a Steriflip 0.2µm
filtering device.
2.9 Discussion
The ability to direct the differentiation of hPSCs to a retinal fate represents a
limitless source of retinal cells for in vitro studies of human retinogenesis, as well
as a unique and exciting tool with which to study retinal disease progression, screen
compounds for potential therapeutic efficacy, and even provide a source of replacement
cells for transplantation purposes. For the above reasons, several groups have explored
the ability to differentiate hPSCs to a retinal fate [8, 10, 11, 30, 32, 53, 76, 78, 80, 97],
with the traditional focus upon the differentiation of photoreceptors and RPE cells
due to the availability of unique and specific characteristics with which to identify
these cells.
The protocol described within this manuscript not only details a method to dif-
ferentiate retinal cells from a pluripotent stem cell population, but this protocol is
significant due to the ability to faithfully identify and enrich for cells at all of the
major stages of retinal development [10, 53, 80]. Starting from an undifferentiated
population of hPSCs, cells are efficiently differentiated to a primitive anterior neu-
roepithelial fate in high purity after as little as 10 days of differentiation (Figure 2.3).
From this point, differentiating cells yield neurosphere populations representing either
forebrain progenitor cells or OV-like retinal progenitor cells, the latter of which exclu-
sively gives rise to more mature retinal phenotypes including photoreceptor cells and
retinal ganglion cells [10,80]. The ability to readily identify cells at each of the major
stages of retinal development is unique to the method outlined in this manuscript,
and helps to establish hPSCs as a valuable in vitro model of human retinogenesis.
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Fig. 2.6. Differentiation of hPSCs to retinal neurons.
Within 90 total days of differentiation, hPSC-derived retinal cells
displayed typical neuronal morphologies under DIC microscopy (A).
Analysis by RT-PCR illustrated an array of retinal-associated tran-
scription factors including those associated with ganglion cells (BRN3
and Islet1), as well as those associated with photoreceptors (CRX
and NeuroD4). Furthermore, proteins associated with phototrans-
duction could also be identified (B). Immunocytochemistry analysis
confirmed the expression of BRN3-positive retinal ganglion cells ex-
tending Map2-positive dendrites (C) as well as photoreceptor-like phe-
notypes including the expression of CRX, OTX2 and Recoverin (D,
E).
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The ability to morphologically identify and isolate retinal progenitor neurospheres
within the first 20-25 days of differentiation is noteworthy for a variety of reasons
(Figure 2.5). First, the use of morphological cues to identify and isolate retinal
progenitor neurospheres represents a novel method of enrichment of retinal cells apart
from other cellular lineages that may be found in such cultures, effectively yielding
highly enriched populations of retinal progenitor cells that can readily differentiate
into all of the major cell types of the retina [10, 30]. Furthermore, this ability to
highly enrich for retinal progenitor cells allows for the more definitive identification
of mature retinal cell types, including retinal ganglion cells. Within the retina itself,
retinal ganglion cells are often identified by the expression of the transcription factor
BRN3 [109–111]. However, this transcription factor is also expressed in other neural
cell types, including some auditory neurons [110,112] as well as many somatosensory
neurons [39, 113]. Thus, when starting with a pluripotent stem cell source that has
the potential to give rise to any cell type of the body, the expression of BRN3 by
itself is not sufficient to definitively identify cells as retinal ganglion cells. However,
due to the ability to enrich for retinal progenitor cells from hPSCs as described by
the current protocol, traditional markers such as BRN3 can be utilized to identify
these retinal cells as other non-retinal cell types will be effectively eliminated from
the culture system. The ability to identify BRN3-positive cells from a highly enriched
retinal progenitor population allows for the more definitive identification of these cells
as retinal ganglion cells.
Due to the ease of hPSC differentiation described in this protocol, including the
minimal culture conditions required to achieve this differentiation event, this proce-
dure allows for the application of hPSCs as a novel model for in vitro studies of human
retinogenesis [10,30,53,80,96,107]. The ability to identify each of the major stages of
retinal development has led to the recent use of this method as a means of studying
the molecular basis for cell fate determination in the retina between those cells of
the neural retina and the retinal pigment epithelium [96, 107]. Not only are these
results significant due to the ability to study these events in human cells, but these
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cell fate determination events are known to occur at stages of development that would
otherwise be inaccessible to experimental investigation. Furthermore, recent studies
have expanded upon this method to generate three-dimensional stratified retinal-like
structures in vitro [30,114], allowing for future studies of cell fate determination and
subsequent maturation of retinal cells.
The ability to derive a full complement of retinal cell types from hPSCs also al-
lows for the study of human inherited diseases of the retina, particularly those leading
to blindness such as age-related macular degeneration (AMD), retinitis pigmentosa,
and optic neuropathies including glaucoma. Owing to the ability to enrich for retinal
progenitor cells with this protocol, large numbers of retinal cells are readily obtain-
able from patient-derived induced pluripotent stem cells, and this ability has recently
been utilized as an effective in vitro model for a variety of blinding disorders, includ-
ing gyrate atrophy and Best disease [10, 82]. The use of hPSCs to generate RGCs
and model glaucoma has been relatively ignored due to issues identifying RGCs from
a pluripotent source. As such, the characterization and exploration of hPSC-derived
RGCs as a model for glaucomatous neurodegeneration is explored in the next chapter.
The potential also exists for pharmacological screening of novel compounds for ther-
apeutic efficacy using patient-derived cells. This was originally described in disorders
affecting the RPE [10,82] and has been expanded to disorders affecting other retinal
cell types such as and glaucoma, as discussed in chapter 3. hPSCs are an effective
complement to traditional model systems and thus bridge an important gap for both
basic and translational research between traditional model systems and the existing
human condition.
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2.10 Critical paramaters
2.10.1 Passaging hPSCs
It is crucial to minimize the amount of pipetting as even a little excessive pipetting
can result in a dramatic decrease in the yield of EBs. Cells that have been treated
with dispase should lift off with little effort.
When cells have been collected into their respective tubes (expansion or differen-
tiation), allow at least 5 minutes for cells to fully settle at the bottom to ensure no
cells are being aspirated with the supernatant.
2.10.2 Plating embryoid bodies with 10% FBS
EBs must be plated at a critical density to ensure the proper differentiation into
neuroepithelium. Without close proximity to neighboring cells, cell survival decreases.
When plated at too high of a density, cells will lack the space they require to develop
properly. Agitation of plates when placed into the incubator also helps in achieving
a uniform distribution of cells within the well.
2.10.3 Manually separating retinal neurospheres
Separation of retinal neurospheres by day 25 is critical to ensure that morphology
can be definitively used to separate retinal and non-retinal cells. After day 25, the
retinal morphology may begin to disappear as the neurospheres continue proliferating.
2.10.4 Maintenance of retinal neurospheres
When changing medium of cells in suspension, unnecessary cell loss can be avoided
by rinsing the well or dish with extra medium. This ensures all cells are collected and
receive fresh medium in a timely manner.
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2.10.5 Anticipated results
The use of this procedure yields a 90% pure population of CHX10-positive retinal
progenitor cells that can be further differentiated into every retinal cell type.
2.10.6 Time considerations
With practice, passaging of hPSCs can take as little as 20 minutes once the nec-
essary supplies and reagents have been prepared. When EBs are ready to be plated
down, this process should take about 10 minutes for three plates. Manually separating
retinal neurospheres from a mixed population can take anywhere from 30 minutes to
an hour, depending on the yield of neurospheres and the experience of the researcher.
Using accutase to disassociate neurospheres can take anywhere from 10 minutes to
40 minutes, with varying neurosphere size and the degree to which spheres are meant
to be disassociated.
2.11 Acknowledgements
Sarah K. Ohlemacher: Conception and design, financial support, collection and/or
assembly of data, data analysis and interpretation, manuscript writing, final approval
of manuscript.
Clara L. Iglesias: Conception and design, collection and/or assembly of data, data
analysis and interpretation.
Akshayalakshmi Sridhar: Conception and design, collection and/or assembly of
data, data analysis and interpretation.
David M. Gamm: Conception and design, financial support.
Jason S. Meyer: Conception and design, financial support, collection and/or as-
sembly of data, data analysis and interpretation, manuscript writing, final approval
of manuscript.
40
3. STEPWISE DIFFERENTIATION OF RETINAL
GANGLION CELLS FROM HUMAN PLURIPOTENT
STEM CELLS ENABLES ANALYSIS OF
GLAUCOMATOUS NEURODEGENERATION
3.1 Introduction
Human pluripotent stem cells offer the unique and unprecedented ability to study
the differentiation of specific cellular lineages, particularly at those stages of develop-
ment that would otherwise be inaccessible to investigation. As such, they have been
demonstrated to serve as powerful in vitro models for human ontogenesis [115, 116].
When derived from specific patient populations, human induced pluripotent stem cells
are capable of serving as in vitro models of disease progression [10, 61, 82, 117–119],
effectively bridging the gap between basic and translational research. Among the
diseases that may be effectively modeled with hiPSCs, those affecting the retina have
been of particular interest [10,82,120–122] as a number of methods exist to derive all
of the major cell types of the retina [10–12, 30, 32, 53, 77, 78, 80, 123] and no effective
treatments and cures exist for many blinding disorders.
While many previous studies have focused upon the ability to derive and utilize
retinal cells such as photoreceptors and RPE [10–12,30,32,53,77,78,80,82,123,124],
RGCs have been largely overlooked to date. As the projection neurons of the retina,
RGCs effectively serve as the connection between the eye and the brain. Furthermore,
RGCs are the predominant affected cell type in a group of diseases known as optic
neuropathies, the most common of which is glaucoma with a current incidence of over
60 million individuals worldwide [56, 125]. Within the context of the retina, RGCs
are often identified by the expression of a limited set of markers that are specific to
these cells. However, when derived from a pluripotent cell source, these markers are
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no longer specific for RGCs as they are expressed elsewhere in the nervous system. To
date, the detailed description and utilization of hPSC-derived RGCs has been largely
lacking due to the shortage of reliable markers with which to definitively identify
these cells. Thus, a systematic, detailed analysis of hPSC-derived RGCs is warranted
in order to serve as a comprehensive in vitro model of RGC development, as well as
the application of patient-derived RGCs for disease modeling.
To this end, efforts were undertaken to comprehensively detail the differentiation
of RGCs, with subsequent application of these approaches to a glaucoma patient-
derived line of hiPSCs. Lines of hPSCs were directed to differentiate in a stepwise
manner specifically toward a retinal lineage and highly enriched populations of retinal
progenitor cells were readily identified and isolated, yielding a highly purified popula-
tion. Upon further differentiation of these retinal progenitor cells, presumptive RGCs
were identifiable within a total of 40 days of differentiation and were characterized
for morphological, phenotypic, and physiological features of native RGCs. These
cells were found to express all of the observed features associated with in vivo RGCs
and importantly, the possibility was excluded to have differentiated into alternate
lineages bearing similar phenotypic markers. Furthermore, hPSC-derived cells pos-
sessed expected physiological properties of RGCs [31, 126]. Following the conclusive
identification and characterization of hPSC-derived RGCs, similar approaches were
undertaken for hiPSCs derived from a glaucoma patient possessing an E50K mutation
in the Optineurin gene, responsible for some familial forms of glaucoma [127–133].
The E50K mutation in OPTN are dominant but relatively rare, occurring in approx-
imately 3-13% of patients with POAG [127,128]. E50K hiPSCs were differentiated to
an RGC fate, at which point their ability to serve as an in vitro model for studies of
disease progression and drug screening were tested. The results of these studies sup-
port a role for hPSCs as an effective in vitro model for human RGC development and
functionality, as well as for use in studies of cellular mechanisms underlying disease
progression in optic neuropathies.
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3.2 Materials and methods
3.2.1 Maintenance of hPSCs
hPSCs were maintained as previously described [12, 80]. Briefly, three lines of
control human pluripotent stem cells (H9, H7 and miPS2) were used, and three
lines of patient-derived induced pluripotent stem cells from an OPTN E50K patient
were derived. All cell lines were maintained in the pluripotent state with mTeSR1
medium (Stemcell Technologies, Vancouver, BC, Canada) on matrigel-coated 6-well
plates. Cells were passaged upon reaching confluency of approximately 70%. Areas
of spontaneous differentiation were initially identified by their distinct appearance
and were mechanically removed. Colonies of hPSCs were then enzymatically lifted
with dispase (2 mg/mL) for approximately 15 minutes and passaged at a ratio of 1:6
onto freshly-coated matrigel plates in mTeSR1 medium. Passaging of hPSCs typically
occurred every 4-5 days.
3.2.2 Differentiation of hPSCs
Differentiation of hPSCs to a retinal lineage was performed with modifications to
previously established protocols (see Chapter 2) [12,53]. Briefly, EBs were generated
from undifferentiated colonies of hPSCs by lifting adherent cultures with dispase. EBs
were gradually transitioned into NIM consisting of DMEM/F12 (1:1), N2 supplement,
MEM nonessential amino acids and heparin (2 µg/mL). After a total of 7 days of dif-
ferentiation, EBs were plated onto uncoated 6-well plates and induced to adhere by
the addition of 10% FBS overnight. The next day, NIM was replaced without FBS
and medium was subsequently changed every other day until day 16. At this point,
cells were lifted from plates by mechanical scraping or pipetting to dislodge colonies
and generate neurospheres in suspension cultures. Neurospheres were maintained in
RDM consisting of DMEM/F12 (3:1), MEM non-essential amino acids, B27 supple-
ment, and antibiotics. Medium was replenished every 2-3 days thereafter until the
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desired day of differentiation was reached. At this point, retinal neurospheres were
isolated according to previously established protocols [10, 12, 30, 80, 107] based upon
morphological cues exhibited by the neurospheres. As indicated in some experiments,
E50K hiPSC-derived neurospheres were treated with either BDNF (100 ng/mL) or
PEDF (100 ng/mL) from day 50 to day 70 of differentiation. Neurospheres were
either harvested for RNA analysis, or partially dissociated with accutase and plated
onto poly-D-ornithine/laminin-coated coverslips for immunocytochemical analysis.
3.2.3 Reprogramming of fibroblasts to hiPSCs
The generation of E50K glaucoma patient hiPSCs was performed using mRNA
reprogramming strategies as previously described [134]. Synthetic mRNAs with a
microRNA booster kit (Stemgent, San Diego, CA) were introduced into E50K fi-
broblasts through the use of Stemfect Transfection Reagent following manufacturers
instructions. mRNAs were transfected daily for a total of 14 days. Within the first
20 days of reprogramming, some fibroblasts began to lose their elongated morphology
and displayed the typical tightly packed morphology of hiPS cell colonies. Individ-
ual colonies of prospective hiPSCs were identified, manually isolated, and clonally
expanded to yield lines of patient-specific hiPSCs. Newly established lines of hiPSCs
were maintained as described above.
3.2.4 RT-PCR
RNA was isolated from retinal neurospheres using the Picopure RNA Isolation
Kit (LifeTechnologies, Carlsbad, CA), with subsequent cDNA synthesis achieved uti-
lizing the iScript cDNA synthesis kit (BioRad, Hercules, CA). PCR analysis was
accomplished using Go-Taq PCR Master Mix (Promega, Madison, WI), while qPCR
analysis was performed with SybrGreen (Life Technologies, Carlsbad, CA). For RT-
PCR experiments, reactions were performed for 35 cycles and products were run
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on 2% agarose gels. Primers for RT-PCR and qRT-PCR analysis can be found in
Supplemental Table 6.2 and Supplemental Table 6.3.
3.2.5 Immunocytochemistry and data quantification
Samples were collected at indicated timepoints of differentiation and plated on
poly-D-orinithine and laminin-coated coverslips. Cells were fixed in a 4% paraformalde-
hyde and PBS for 30 minutes. Alternatively, neurospheres were processed for cryostat
sectioning as indicated. For this purpose, neurospheres were fixed in 4% paraformalde-
hyde and PBS for 45 minutes and then introduced into a 20% sucrose solution in PBS
for equilibration overnight at 4 ◦C. The following day, sucrose solution was aspirated
and changed to a 30% sucrose solution at 4 ◦C. Following equilibration, neurospheres
were embedded in OCT, frozen in dry ice and stored at −80 ◦C until sectioning.
Cryostat sections were cut at a thickness of 10µm and stored at −80 ◦C until use for
immunocytochemistry.
For immunostaining of both coverslips and cryostat slides, samples were initially
washed three times with PBS and permeabilized with 0.2% Triton X-100 for 10 min-
utes at room temperature. 10% donkey serum in PBS was used as a blocking agent
for one hour at room temperature and primary antibodies (Supplemental Table 6.1)
were applied in a solution consisting of 5% donkey serum and 0.1% Triton X-100
overnight at 4 ◦C. The next day, samples were washed with PBS and 10% donkey
serum blocking agent was applied for 10 minutes at room temperature. Samples were
treated with secondary antibodies diluted in a 5% donkey serum and 0.1% Triton
X-100 solution for one hour at room temperature, followed by 3 washes with PBS.
Samples were mounted onto slides and cells were imaged with either a Leica (Wetzlar,
Germany) DM5500 fluorescence microscope or an Olympus (Shinjuku, Tokyo, Japan)
Fluoview 2000 confocal microscope.
Quantification of cell counts was performed with ImageJ software using immunos-
tained samples. For each experimental condition, three different lines of hPSCs were
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utilized. Within these different cell lines, a minimum of three images were collected
from at least three separate experiments performed at different passage number from
each cell line. Each image was quantified to calculate the percentage of BRN3-positive
cells, as well as the abundance of activated caspase-3 expression relative to the total
number of BRN3-positive cells. ANOVA statistical analyses or students t-tests were
performed with Prism software (Graphpad, La Jolla, CA) to determine statistically
significant differences at a p-value of less than 0.05. Size of the Golgi complex was
determined by GM130 staining similar to previous reports [107, 134, 135] by calcu-
lating the total area of GM130-positive staining utilizing ImageJ software, and then
dividing this number by the total number of DAPI-positive nuclei. A minimum of
three samples were analyzed per experiment to obtain the average Golgi area per cell.
A students t-test was used to determine statistical significance using Prism software,
and significant differences were identified at a p-value less than 0.05.
3.2.6 Electrophysiology
Whole-cell patch-clamp recordings were carried out at 21 ◦C as previously de-
scribed [136] using an EPC-10 amplifier and the Pulse8.31 program (HEKA, Lam-
brecht/Pfalz, Germany). Fire-polished electrodes were fabricated from borosilicate
capillary glass (1.2-mm outer diameter, 0.69-mm inner diameter; Sutter Instrument
Co., Novato, CA) using a P-97 puller (Sutter Instrument Co., Novato, CA). After
filling with the intracellular solution containing (in mM): KCl 140, MgCl2 5, EGTA
5, CaCl2 2.5, Hepes 10, ATP 4, GTP 0.3, Phosphocreatine 8, pH7.3 (adjusted with
KOH), the access resistance of electrode pipettes ranged between 4 and 5 M. The
bathing solution contained (in mM): NaCl 140, MgCl2 1, KCl 5, CaCl2 2, Hepes 10,
Glucose 10, pH7.3 (adjusted with NaOH). After establishing the whole-cell recording
configuration, cells were allowed to stabilize for 2-3 minutes in current-clamp mode
before initiating ramp current injection to measure action potential activity. Cells
were held at -100 mV to stabilize for 5 minutes in voltage-clamp mode before apply-
46
ing depolarizing voltage steps to measure potassium and sodium currents. A -P/4
subtraction protocol was used to remove linear leak current and capacitance artifact
for all voltage clamp recordings. Voltage errors were minimized using more than 80%
series resistance compensation. Membrane currents were filtered at 5 kHz and sam-
pled at 20 kHz. Tetrodotoxin (TTX, 5µM) and tetraethylammonium (TEA, 100µM)
stock solutions were made using the bathing solution. TTX or TEA was diluted into
a 300 µL recording chamber to achieve the final concentration.
3.3 Results
3.3.1 Identification of hPSC-derived retinal ganglion cells
The definitive identification of RGCs from a pluripotent source has been compli-
cated by the lack of specific markers to identify these cells. The expression of the
transcription factor BRN3 has been widely utilized to identify cells with RGC-like
characteristics [10–12, 20, 23, 30, 77, 78, 80, 114]. However, when derived from hPSCs,
such markers lose their specificity as BRN3 is also expressed in other cell types of the
central nervous system, particularly hair cells of the auditory system [40] as well as
somatosensory neurons [39]. Thus, to conclusively establish the RGC nature of hPSC-
derived RGCs, their derivation and identification necessitates the detailed stepwise
differentiation through early neural and retinal progenitor intermediaries.
To this end, initial efforts were focused upon the differentiation and definitive
identification of hPSC-derived RGCs. As a starting point, hPSCs were directed to
differentiate to an optic vesicle-like stage of retinogenesis as previously described
[10, 12, 30, 80, 114], at which point highly enriched populations of CHX10-positive
retinal progenitor cells comprised 90.02% ± 1.95% of all neurospheres. These retinal
populations were readily identified and isolated from their non-retinal forebrain coun-
terparts based upon morphological cues (Figure 3.1A-C), allowing for the subsequent
classification of further differentiated phenotypes to the retinal lineage. Within 40
total days of differentiation, enriched populations of optic vesicle-like retinal neuro-
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Fig. 3.1. Definitive identification of presumptive RGCs using BRN3
expression in differentiated cultures of hPSCs.
After 25 days of differentiation, two morphologically distinct popu-
lations of neurospheres were observed (A), from which optic vesicle-
like neurospheres were identified and isolated based upon their phase-
bright appearance (B). Isolated optic vesicle neurospheres were highly
enriched for CHX10-expressing retinal progenitor cells (C). After a to-
tal of 40 days of differentiation, RT-PCR analysis demonstrated that
presumptive RGCs expressed BRN3 in conjunction with other retinal
markers, but not markers of other neuronal BRN3-expressing lineages
(D). Genomic DNA (Gen.) served as a positive control for RT-PCR
experiments. Immunocytochemical analysis confirmed expression of
BRN3 localized with other retinal markers (E-F). BRN3 remained
distinctly separate from Recoverin photoreceptors (G).
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spheres began to express BRN3 as well as a compliment of other retinal-associated
transcription factors when analyzed by RT-PCR (Figure 3.1D). Conversely, no ex-
pression of genes characteristic of the auditory [40] and somatosensory [39] lineages
was detected. Taken together, these results confirm the retinal phenotype associated
with these BRN3-positive cells. Immunocytochemistry analysis further confirmed the
expression of BRN3 with other markers of the retinal lineage (Figure 3.1E-G). Specif-
ically, BRN3 expression was often found colocalized with markers typically associated
with retinal progenitor cells and some RGCs such as PAX6 and SIX6. However, colo-
calization of BRN3 with markers indicative of other retinal cell types such as MITF
was not observed (Figure 3.2).
SCFig2.pdf
The temporal birth order of specific retinal cell types has been well characterized in
vivo, with retinal progenitors giving rise to RGCs and cone photoreceptors early while
rods and Muller glia emerge later [89, 137]. Through immunocytochemical analysis,
early stages of this stepwise progression to an RGC fate could be observed (Figure
3.3A), with PAX6-positive neural progenitors the first stage in this differentiation
process. Following the identification and isolation of retinal neurospheres, robust
differentiation of CHX10-positive retinal progenitors was observed. The appearance
of BRN3-expressing RGCs could be observed shortly thereafter, followed by the onset
of recoverin-positive photoreceptor-like cells. RT-PCR analysis further confirmed this
stepwise pattern of retinal fate determination (Figure 3.3B).
3.3.2 Characterization and functional analysis of hPSC-derived retinal
ganglion cells
The expression of BRN3, along with the differentiation of hPSCs through the step-
wise process of retinal differentiation, aided in the identification of resultant RGCs.
Overall, approximately 36.1%±1.7% of cells expressed the RGC-associated transcrip-
tion factor BRN3 within the first 40 days of differentiation (Figure 3.4A). Beyond
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Fig. 3.2. Co-localization of RGC markers with markers of other retinal
cell types.
BRN3 exhibited high-colocalization with the RGC-associated marker
ISLET1 (A). RGCs labeled with BRN3 and ISLET1 showed very little
co-expression with photoreceptors (B), glia (C), amacrine cells (D),
RPE (E), or astrocytes (F). Quantification of BRN3 co-expression
with RGC associated markers PAX6, ISLET1, and SIX6 and little to
no co-expression with other retinal cell types (G). Error bars represent
s.e.m.
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Fig. 3.3. hPSC-derived RGCs are generated in a temporally appro-
priate sequence.
Immunocytochemistry analysis revealed that BRN3-positive RGCs
appeared subsequent to the establishment of neural (PAX6) and
retinal (CHX10) progenitor fates, but prior to the generation of
photoreceptor-like (Recoverin) cells (A). qRT-PCR analysis confirmed
that genes associated with retinal and RGC development were ex-
pressed at developmentally-appropriate timepoints, with those genes
associated with retinal progenitors expressed prior to the onset of
RGC-specific genes (B).
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the expression of BRN3, however, a variety of other features are associated with the
development of RGCs. Upon differentiation, presumptive RGCs co-expressed a wide
array of such factors associated with RGC specification (Figure 3.4B-E). Further-
more, maturation and morphological changes of these cells were readily observed, as
BRN3-positive RGCs were found associated with MAP2-positive neurite extensions
(Figure 3.4F). Interestingly, a small population of melanopsin-expressing cells were
observed, indicative of ipRGCs, of which there are five subtypes, M1-M5. These cells
expressed high levels of Melanopsin (Figure 3.4G) and largely lacked BRN3 expres-
sion (Figure 3.4G insert), typical of the M1 class of ipRGCs, which are one of the few
RGC subtypes that do not express BRN3 [138–140].
The ability to exhibit lengthy neurite outgrowths is a defining characteristic of
RGCs when compared to other neurons of the retina. Following prolonged growth
in vitro, extensive neurite outgrowth was readily observed from BRN3-expressing
RGCs (Figure 3.4H). Cytoskeletal components became compartmentalized with clear
separation of MAP2 expression in somatodendritic regions and Tau expression con-
fined to axonal extensions that fasciculated and extended over long distances. The
progressive acquisition of RGC characteristics, as well as the differential expression
of these characteristics apart from non-retinal forebrain cells, was further character-
ized by qRT-PCR analysis (Figure 3.4I-J). In comparison to retinal progenitor cells
identified at earlier stages of differentiation, RGC populations exhibited a robust in-
crease in the expression of RGC-associated genes, along with a significant decrease
in the expression of retinal progenitor-associated genes (Figure 3.4I). Furthermore,
when compared to age-matched non-retinal forebrain populations as indicated above
(Figure 3.4A), a significant increase was observed in the expression of retinal and
RGC-associated genes (Figure 3.4J).
As projection neurons connecting the eye with the brain, and unlike most other
neurons of the retina, RGCs transmit visual information via elicitation of action
potentials through the use of voltage-gated ion channels [31]. To confirm whether
hPSC-derived RGCs are capable of similar physiological activity, prospective RGCs
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Fig. 3.4. Phenotypic characterization of hPSC-derived RGCs.
After 40 days of differentiation, BRN3-positive RGCs comprised ap-
proximately 36.1 ± 1.7% of the total differentiated population (A).
BRN3-positve RGCs expressed numerous RGC-associated markers
(B-E), and began to extend MAP2-positive neurites (F) within a to-
tal 70 days of differentiation. A small subset of intrinsically photo-
sensitive melanopsin-positive RGCs were observed that were BRN3-
negative (G) by 70 days of differentiation. Prolonged differentiation
gave rise to elaborate RGC-like morphologies exhibiting compartmen-
talized expression of MAP2 and TAU, including fasciculated TAU-
positive axons (H) within 100 total days of differentiation. qRT-PCR
analysis revealed that BRN3-expressing cells exhibited increased ex-
pression of RGC-associated transcripts compared to their retinal pro-
genitor precursors (I), as well as their age-matched non-retinal fore-
brain counterparts (J). Significant differences indicated as * = p<0.05,
** = p<0.01, *** = p<0.005, **** = p<0.001.
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were first morphologically identified for electrophysiological analysis based upon ex-
tensive neurite outgrowth (Figure 3.5A) typical of these cells [12,141].
Electrophysiological activity of hPSC-derived RGCs was then analyzed by patch
clamp analysis, and recorded cells were filled with Lucifer Yellow for subsequent
immunocytochemical analysis for BRN3 expression to definitively identify analyzed
cells as RGCs (Figure 3.5B). hPSC-derived RGCs demonstrated the ability to fire
action potentials (Figure 3.5C) and exhibited a hyperpolarized resting membrane
potential (RMP) (Figure 3.5D). These electrophysiological properties were associated
with ionic currents, including outward flow that could be blocked by the addition of
TEA, indicating the presence of voltage-gated K+ channels (Figure 3.5E-F), as well
as inward current flow that was sensitive to the voltage-gated Na+ channel blocker
TTX (Figure 3.5G-H). Furthermore, both K+ and Na+ ionic currents were shown to
be voltage-dependent in nature.
3.3.3 In vitro modeling of optic neuropathies using patient specific hiP-
SCs
The ability to derive RGCs from an hPSC source has important implications
beyond studies of developmental biology [115, 116]. Translational applications in-
clude [10,61,82,118] in vitro disease modeling and pharmacological screening [142–144]
when derived from specific patient sources. Mutations in the OPTN gene have
been extensively documented to result in severe RGC degeneration associated with
POAG [127–132] and therefore, should provide an effective in vitro tool for studies
of underlying disease mechanisms, as well as subsequent pharmacological screening.
To this end, skin fibroblasts from a patient possessing an E50K missense mutation in
the OPTN gene were reprogrammed to pluripotency, exhibiting robust expression of
a full complement of pluripotency-associated factors (Figure 3.6) and the ability to
give rise to cell types of all three germ layers (Figure 3.7).
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Fig. 3.5. Physiological analysis of hPSC-derived RGCs.
Patch clamp analysis was performed and retinal ganglion cell mor-
phologies were highlighted by DIC microscopy, including long neurite
outgrowth in RGCs derived between 80-90 total days of differenti-
ation (A). Recorded cells were filled with Lucifer Yellow for subse-
quent immunocytochemical confirmation of their RGC identity (B).
hPSC-derived RGCs demonstrated the ability to fire action potentials
(C) and exhibited a hyperpolarized resting membrane potential (D).
These features were associated with the conductance of potassium
and sodium through voltage-gated channels, which could be blocked
by the addition of either TEA (E-F) or TTX (G-H).
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Fig. 3.6. Establishment of E50K patient-specific hiPSCs.
Fibroblasts from a glaucoma patient exhibiting an E50K mutation in
the OPTN gene (A) were reprogrammed to yield hiPSCs, with resul-
tant cells demonstrating immunoreactivity to pluripotency-associated
transcription factors including OCT4, SOX2, and Nanog as well as the
cell surface antigens SSEA4, Tra-1-60 and Tra-1-81 (B-D). Sequence
analysis confirmed the presence of the E50K mutation in patient cells
(E). Karyotype analysis of E50K hiPSCs exhibited no abnormalities
in resultant cell lines (F).
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Upon differentiation, enriched populations of E50K hiPSC-derived retinal neu-
rospheres (Figure 3.8A) were characterized by robust expression of CHX10 (Figure
3.8B), indicative of a retinal progenitor state [10,105,107]. Subsequent differentiation
of these retinal progenitors yielded BRN3-positive cells that could be definitively iden-
tified as RGCs due to their retinal lineage. These RGCs exhibited elaborate MAP2-
positive neuronal morphologies and formation of complex neural networks (Figure
3.8C-D). To further examine the applicability of E50K hiPSC-derived RGCs as an
in vitro model for glaucoma, the activation of caspase-3 was analyzed and quantified
via immunocytochemistry in comparison to unaffected control lines. In undifferenti-
ated cultures, little activation of caspase-3 was observed and no significant differences
were seen between control and E50K hiPSCs (Figure 3.8E-G). Upon differentiation of
these cells to the affected RGC cell type, caspase-3 activation was minimal in control
hiPSC-derived RGCs but was significantly increased in E50K hiPSC-derived RGCs
(Figure 3.8H-J). Given these increased levels of apoptosis, the ability of these cells to
serve as a tool for pharmacological screening was subsequently tested, utilizing factors
previously identified as neuroprotective in other systems [145–150]. Upon treatment
of E50K hiPSC-derived RGCs with either BDNF or PEDF, a significant reduction in
caspase-3 activation was observed (Figure 3.8K-M).
Interestingly, undifferentiated E50K hiPSCs also exhibited a disorganized Golgi
morphology that led to a significant increase in size (Figure 3.9A-C), as previously
reported [130, 131, 136]. However, differentiation to the affected RGC phenotype
yielded no significant difference in the size and organization of the Golgi of E50K
RGCs compared to control RGCs (Figure 3.9D-F).
3.4 Discussion
The results presented here demonstrate the robust derivation and definitive iden-
tification of RGCs from hPSCs as identified by the combination of morphological,
phenotypic, and physiological measures. Furthermore, these efforts were applied to
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Fig. 3.7. Confirmation of pluripotency by differentiation analysis.
Upon spontaneous differentiation, E50K hiPSCs were capable of giv-
ing rise to cellular lineages of each of the three germ layers, including
ectoderm (A), mesoderm (B), and endoderm (C).
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Fig. 3.8. Patient-derived hiPSCs can be utilized as an effective model
of RGC neurodegeneration.
E50K patient hiPSCs were directed to differentiate to a retinal progen-
itor fate (A-B). Retinal ganglion cells were subsequently differentiated
and characterized by the expression of BRN3 and the development
of complex neural networks (C-D). In the pluripotent state, control
and E50K hPSCs exhibited no significant differences in apoptosis (E-
G). Following differentiation for 70 days, E50K RGCs demonstrated
significantly increased apoptosis (H-J), which could be significantly
reduced by treatment with select neuroprotective factors (K-M). Sig-
nificant differences indicated as * = p<0.05, *** = p<0.005.
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establish an in vitro model of glaucoma using patient-derived hiPSCs. This allowed
for the ability to study associated underlying features of the disease itself, as well as
provide a platform for pharmacological screening [142].
Although previous reports have demonstrated that hPSCs can acquire retinal
characteristics upon differentiation [10, 12, 30, 53, 78, 80, 114], including features of
retinal ganglion cells [10–12,20,22,23,30,53,54,77,78,80,114], many markers used to
identify RGCs, particularly BRN3, are also expressed in other neural cells, including
some auditory neurons [40] as well as somatosensory neurons [39]. Thus, efforts to un-
equivocally assign an RGC identity are complicated without thorough and systematic
characterization. Moreover, BRN3 exists in three different forms, BRN3A, BRN3B,
and BRN3C [109, 151]. While the current studies analyzed the overall expression of
BRN3, it is likely that most of the cells expressed BRN3B, as this form is known to
play a critical role in the differentiation and survival of RGCs, and is also known to
be expressed earlier in development than other forms of BRN3.
In the current study, multiple approaches were undertaken to ensure that pre-
sumptive RGCs had indeed adopted this fate. First, retinal differentiation proceeded
through a retinal progenitor stage that could be readily identified and isolated, yield-
ing highly enriched populations of CHX10-expressing retinal progenitor cells, with
subsequent expression of BRN3 allowing for more definitive identification of RGCs.
Additionally, BRN3 expression was often found expressed in close association with
other retinal cell types, while expression of markers associated with auditory and
somatosensory lineages was not observed. Thus, the data presented provides the
strongest evidence to date of the ability to conclusively differentiate RGCs from hP-
SCs.
Intrinsically photosensitive retinal ganglion cells are a specific subtype of RGC
that function in non-visual phototransduction processes including circadian entrain-
ment and pupillary responses [138–140]. The data presented within the current study
is the first to demonstrate the differentiation of ipRGCs from hPSCs, as detected by
the expression of the phototransduction protein melanopsin. While the derivation of
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these cells was exceedingly rare, the presence of these cells allows for future investi-
gation into the developmental specification of ipRGCs, as well as studies analyzing
the damage and loss of ipRGCs in a variety of injuries and degenerative disorders of
the retina.
Beyond phenotypic features, these hPSC-derived RGCs also possessed appropri-
ate morphological and physiological features. After prolonged growth in vitro, hPSC-
derived RGCs were capable of extensive neurite outgrowth, which was specifically
directed toward other aggregates of cells, perhaps due to paracrine signaling. Further
maturation of hPSC-derived RGCs was also observed in the compartmentalization
of MAP2 and Tau, cytoskeletal proteins that are found widely expressed in imma-
ture neurons but whose expression becomes confined to somatodendritic and axonal
regions, respectively, in mature neurons [152]. Furthermore, hPSC-derived RGCs ex-
hibited the ability to function physiologically, with the ability to conduct sodium and
potassium through voltage-dependent channels as well as the ability to fire action po-
tentials. Although these features are characteristic of many types of neurons [31], in
the retina these characteristics are specifically found within the RGCs as well as a sub-
set of amacrine cells. While these cells exhibited a hyperpolarized resting membrane
potential, this potential was recorded at an average of approximately -35 mV, indicat-
ing that these cells have not yet reached a fully mature state. Future experiments will
necessitate the development of methods to derive fully mature hPSC-derived RGCs.
Efforts were also focused on the development of hiPSC-based models of optic neu-
ropathies. Glaucoma is the most prevalent of the optic neuropathies, with a current
incidence of more than 60 million individuals worldwide [56,125]. However, a variety
of factors exist which are causative or at least associated with the onset of glauco-
matous neurodegeneration [153, 154]. Mutations in the OPTN gene were selected
for study, particularly the E50K mutation which has been previously demonstrated
to result in a particularly severe neurodegenerative phenotype [127, 128, 130]. While
the results obtained with these cells will be of significance for future studies of this
glaucoma-associated genotype, these results could also prove to be more profound
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Fig. 3.9. Lack of Golgi deficits in E50K hiPSC-derived RGCs.
Fragmentation of the Golgi complex was detected in undifferentiated
cultures of E50K hiPSCs compared to control hiPSCs (A-C). Upon
differentiation to the affected RGC cell type, no significant differences
in Golgi size were observed between control and E50K hiPSC-derived
RGCs (D-F). Significant differences indicated as ** = p<0.01
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for other glaucoma phenotypes as well. As other factors such as elevated intraocu-
lar pressure have been suggested to serve as a trigger for subsequent degeneration
of RGCs [154], mutations in genes including OPTN could provide a similar trigger,
with downstream effects mimicking features of glaucoma common to many underlying
causes.
Whereas previous studies have analyzed features of glaucoma in RGCs by utilizing
animal models or non-affected cell types in vitro [136,155,156], the development of a
human induced pluripotent stem cell model of glaucoma allows for precise analysis of
the affected cell type. The ability to study features of the disease process in human
cells from the affected cell type is of utmost importance, as some previous studies
have identified disruptions in the Golgi complex as a hallmark of certain mutations
in OPTN, including the E50K mutation [130, 131, 136]. While this phenotype was
recapitulated in undifferentiated E50K hiPSCs, this Golgi fragmentation was not ob-
served upon differentiation to RGCs, the cell type directly affected by the disease
process. Thus, disruptions to the Golgi complex may not have any direct connection
to the health and survival of RGCs and consequently, may not play a role in glau-
comatous neurodegeneration observed in patient samples. Such a result underscores
the importance of hiPSC-based models of inherited diseases and the ability to dif-
ferentiate these cells to the affected cell type. The increased apoptosis observed in
E50K cells appeared to be specific for RGCs, the affected cell type, as no significant
differences were observed in undifferentiated E50K hiPSCs compared to control cell
lines. As such, the development of this in vitro model of glaucoma will allow for
future studies analyzing precise mechanisms underlying glaucomatous neurodegener-
ation. The results of these studies also highlight the potential of hiPSCs to serve as
a tool for pharmacological screening [142–144], as treatment of E50K hiPSC-derived
RGCs with either BDNF or PEDF was able to partially rescue these cells from apop-
tosis. While many growth factors have been shown to play a role in RGC survival,
recent work has demonstrated that BDNF and PEDF are especially important in
the rescue of glaucomatous RGCs [157–161]. In vivo RGCs receive BDNF from the
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LGN and PEDF from Muller glia [157, 158, 162–165]. Interestingly, treatment with
these neuroprotective factors yielded similar levels of cell survival. While the reason
for this similarity is not known, the possibility exists for overlap in these two sig-
naling pathways. While both BDNF and PEDF are known to inhibit the apoptotic
pathway [146–148, 150], they also affect transcription through MEK/ERK signaling
pathways [144]. Thus, the similar net effects produced by BDNF and PEDF could
be due to convergence of these signaling pathways within the cell.
3.5 Conclusion
Taken together, the results of the current study represent the most comprehensive
description of RGC derivation from an hPSC source as well as the ability to utilize
these approaches for studies of optic neuropathies such as glaucoma. On a broader
level, this study establishes the suitability of hPSCs to analyze critical stages of RGC
development from a human source. Furthermore, these results demonstrate the appli-
cability of hPSC-derived RGCs for disease modeling and pharmacological screening
for a host of optic neuropathies, both complementing existing animal models as well
as narrowing the gap to clinical applications. However, the primary limitation of the
current approach is that hPSC-derived RGCs grown in culture have not displayed all
the proper electrophysiological characteristics as demonstrated by in vivo RGCs, in-
cluding a complement of mature electrophysiological properties and the establishment
of pre- and postsynaptic connections. Adult RGCs degenerate in optic neuropathies.
As such, to better serve as physiologically relevant models of disease, the capacity of
hPSC-derived RGCs to fully mature and recapitulate features of adult, in vivo RGCs
is explored in the next chapter.
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4. SYNAPTIC MATURATION OF HUMAN
PLURIPOTENT STEM CELL- DERIVED RETINAL
GANGLION CELLS
4.1 Introduction
The retina is linked to the brain by the optic nerve, a complex bundle of RGC
axons, astrocytes, vasculature and oligodendrocytes. Damage of the optic nerve leads
to common forms of blindness termed optic neuropathies, the most common of which
is glaucoma [56, 166] . Onset of these disorders tends to be gradual and upwards of
50% of RGC axons have irreversibly degenerated by the time a patient observes any
vision changes [4, 58]. Furthermore, RGCs possess no capacity for regeneration into
adulthood. This necessitates the development of neuroprotective strategies for early
stages of disorders and cell replacement therapies for end stages of diseases once RGCs
have degenerated. hPSCs can provide an unlimited supply of RGCs for generation of
cell replacement and drug screening therapies for optic neuropathies [5, 6, 52].
In order for hPSC-derived RGCs to be used for therapeutic applications, they
must be able to fully recapitulate the features of the affected cell type, including the
ability to develop mature phenotypic and functional characteristics. Previous studies
have demonstrated the ability to generate hPSC-derived RGCs through various meth-
ods with great success [9, 10, 12, 13, 21, 30, 50, 167]. These cells have exhibited some
capacity to mimic in vivo retinal ganglion cells, including recapitulating proper de-
velopmental timing and compartmentalized structure [13]. hPSC-derived RGCs have
also been shown to fire APs [13,20,21,25,26,168], maintain a hyperpolarized RMP [13],
respond to neurotransmitters like glutamate [21], and conduct ions through voltage
gated channels [13,20,21,25,26]. Properties of fully mature in vivo RGCs include the
maturation of intrinsic membrane properties such as voltage gated sodium and potas-
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sium channels [126,169,170]. The development of voltage gated channels is essential
as many properties of a mature RGC are governed by these channels including large
amplitude APs [169,170] and repetitive AP firing [126,170]. Mature RGCs also display
a resting membrane potential ranging from -55 to -60mV [126,169,171]. RGCs posses
the largest somas within the retina, ranging from 70µm2 to 400µm2 [18, 172] and
intricate neurites that increase in size and complexity as development proceeds [173].
However, it is unknown when these characteristics emerge and hPSC-derived RGCs
that display a full complement of mature features have been scarce to date.
To address these shortcomings, experiments were undertaken to characterize the
phenotypic maturation and functional capacity of hPSC-derived RGCs in short term
(<2 weeks post-plating) and long term (>2 weeks post-plating) culture. Short term
culture was used to monitor the emergence of neurite complexity while long term
culture was utilized to observe the onset of electrophysiological properties, which are
known to develop more slowly [174]. Additionally, one aspect of this research that has
been largely ignored to date is the effect of astrocytes on RGC development. Within
the retina, the cell bodies of astrocytes reside in the nerve fiber layer and optic nerve
head [175,176]. Astrocytes surround the axons of RGCs as they exit the optic nerve
head to form the optic nerve. In the retina, astrocytes are essential for many func-
tions, including reuptake of neurotransmitters [177], maintenance of the blood-retina
barrier [178], provision of neurotrophic support [179], and importantly, guidance of
synaptogenesis [180, 181]. As such, efforts were untaken to generate hPSC-derived
astrocytes for co-culture with hPSC-derived RGCs to determine the effect upon phe-
notypic development and functional maturation in vitro. Results were compared to
RGCs grown in the absence of astrocytes or in the presence of astrocyte conditioned
medium (ACM) to determine if the effects of astrocytes were paracrine or contact me-
diated. hPSC-derived RGCs displayed some features associated with mature in vivo
RGCs. However, the presence of hPSC-derived astrocytes increased RGC synaptic
complexity and enhanced functional characteristics. The results of this study are
the first of its kind to characterize the phenotypic and functional development of
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hPSC-derived RGCs over time and explore how hPSC-derived astrocytes modulate
the maturation of hPSC-derived RGCs.
4.2 Materials and methods
4.2.1 Maintenance of hPSCs
hPSCs were grown as previously described [10, 12, 13, 50]. In short, hPSCs were
maintained using hESC qualified matrigel (Fisher Scientific, Hampton, NH) on six-
well plates with mTeSR1 medium (StemCell Technologies, Vancouver, Canada) in
incubators containing 5% CO2 at 37
◦C. Once colonies reached approximately 70%
confluency, cells were passaged (every 4-5 days). Before passaging, areas of sponta-
neous differentiation were marked according to their unique morphology and mechan-
ically removed. Passaging occurred by enzymatically lifting colonies using dispase
(2mg/mL) for approximately 15 minutes. Colonies were then split in a 1:6 ratio.
Multiple hPSC-lines were used throughout this study including h7-BRN3:tdTomato-
Thy1.2, TiPS5, and miPS2.
4.2.2 Differentiation of hPSCs into RGCs
hPSCs were differentiated to a retinal fate using previously described protocols
with minor modifications [10, 12, 13, 50]. Briefly, enzymatic lifting of pluripotent
colonies yielded EBs. Over a time course of three days, cells were transitioned from
mTeSR1 medium into NIM (Dubelcos Modified Eagle Medium (DMEM)/F12 (1:1),
100x N2 supplement, MEM nonessential amino acids, heparin (2µg/mL), and an-
tibiotics). At 7 days of differentiation, cells were transferred into a six-well plate
with NIM and adhered by the addition of 10% FBS. The following day, FBS was
removed and fresh NIM was added and then replaced every other day until day 16.
Plated colonies at day 16 were mechanically lifted and transferred into a suspension
culture containing RDM (DMEM/F12 (3:1), MEM nonessential amino acids, B27,
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and antibiotics). Suspension cultures were fed every two days with fresh RDM. After
30 days of differentiation, early retinal organoids could be readily identified by the
bright ring surrounding the periphery. Retinal organoids were isolated from fore-
brain neurospheres. At day 45, retinal organoids were dissociated using accutase
for 20 minutes. Following dissociation, single cells were immunopurified for RGCs
with the Thy1.2 surface receptor using the MACs magnetic cell separation kit (Mil-
tenyi Biotec, Bergisch Gladbach, Germany). Purified RGCs were plated on poly-D-
ornithine, laminin-coated coverslips at a density of 10,000 cells/coverslip and main-
tained in BrainPhys Neuronal Media (StemCell Technologies, Vancouver, Canada)
supplemented with 20ng/mL CNTF. Coverslips were then fixed at 1, 4, 7, and 10
days post-plating and used to analyze RGC phenotypic maturation.
4.2.3 Immunopurification
hPSC-RGCs were purified using a MACS kit based on the Thy1.2 surface recep-
tor driven by the expression of BRN3 in the h7-BRN3:tdTomato-Thy1.2 hPSC line.
Briefly, at 45 days of total differentiation, retinal organoids were dissociated for 20
minutes using accutase. Single cells were then incubated with the CD90.2 microbeads
specific for Thy1.2 for 15 minutes at 4 ◦C in the dark at a ratio of 10µL of beads:
90µL of MACs Rinsing Buffer per 10 million cells. The cell suspension was pipetted
into the MACs MS magnetic column. RGCs were trapped in the magnetic field based
on the attachment of the Thy1.2 microbeads and non-RGCs flowed through the ap-
paratus. The cell suspension was washed 3 times with MACs Rinsing Buffer. To
flush out the RGCs, the MS column was removed from the magnetic field and 1mL
of MACs Rinsing Buffer was added to the column and a plunger was used to push
RGCs out of the column into a collection tube. The MS column was placed back in
the magnetic field, and the 1mL purified RGC cell suspension was re-loaded to the
column and the previous steps were repeated to increase the purity of RGCs. Purified
RGCs were centrifuged, counted, and plated at a density of 10,000 cells/coverslip.
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4.2.4 Differentiation of hPSCs into astrocytes
hPSCs were differentiated to astrocytes using previously described protocols [182,
183]. At 7 days of differentiation, EBs were adhered onto laminin-coated 6 well
plates supplemented with NIM. At day 16, colonies were mechanically lifted using
a P1000 pipette tip and placed in a suspension culture of RDM. Within 40 days of
differentiation, early astrospheres were supplemented with 10 ng/mL EFH (FGF2,
EGF and Heparin). Astrospheres were chopped and expanded using a mechanical
tissue chopper to a size of 200µm every 2 weeks for up to 12 months. Between 9 and
12 months, glial astrospheres were dissociated using accutase for 20 minutes. Single
cells were plated at a density of 20,000 astrocytes/coverslip and supplemented with
BrainPhys Neuronal Media with the addition of 20ng/mL of CNTF to yield GFAP
positive astrocytes. Within 3 weeks of plating, co-cultures of RGCs and astrocytes
were established. 10,000 purified RGCs were plated on top of adhered astrocytes to
create a substrate bound co-culture. Additionally, ACM was collected from plated
astrocytes. ACM was added every second day to RGC cultures at a dilution of 1:1
with fresh BrainPhys as previously described [184] to create a secreted co-culture
environment. Co-culture experiments were fixed 10 days post-plating and analyzed
for RGC maturation.
4.2.5 Histology and immunocytochemistry
hPSC-derived RGC coverslips were collected at 1, 4, 7, and 10 days post-plating.
Samples were fixed with 4% paraformaldehyde for 30 minutes. In preparation for
immunostaining, samples were washed 3 times with PBS and permeabilized in 0.2%
Triton X-100 for 10 minutes at room temperature. This was followed by blocking in
10% donkey serum for one hour at room temperature. Primary antibodies (Supple-
mental Table 6.1) were diluted in 5% donkey serum and 0.1% Triton X-100 solution
and applied to samples overnight at 4 ◦C. The following day, cells were washed 3
times with PBS and blocked with 10% donkey serum for 10 minutes at room temper-
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ature. Secondary antibodies were diluted in 5% donkey serum and 0.1% Triton X-100
solution and added for 1 hour at room temperature. Cells were washed 3 times with
PBS and mounted appropriately. Immunofluorescent images were obtained using a
Leica (Wetzlar, Germany) DM5500 fluorescence microscope.
4.2.6 Quantification and statistical analyses of RGC maturation
Purified RGCs at 1, 4, 7, and 10 days post-plating as well as co-culture experiments
at 10 days post-plating were analyzed for RGC maturation based on soma size and
the number of primary neurites. Numerous biological replicates (n=5) were obtained
at each time point. Immunofluorescent images were captured and analyzed by the
expression of tdTomato driven by BRN3. Using ImageJ plugins, the RGC soma size
area and the number and length of primary neurites were quantified and recorded.
Statistical analyses were performed using One-Way ANOVA followed by Tukey’s post
hoc. Statistical differences were determined based on a p value of less than 0.05.
4.2.7 Western blot
RGCs were collected and sonicated in a 2% SDS solution. Protein concentration
was determined using a BCA assay (ThermoScientific, Waltham, MA) and samples
were normalized so that equal amounts of protein were loaded into each well. Lysates
were mixed with 4x Sample Buffer plus DTT and loaded onto 4-15% gradient gels.
Gels were transferred to nitrocellulose using the Trans-Blot Turbo system (BioRad,
Hercules, CA), blocked with 5% milk in tris buffered saline (TBS) plus 0.1% tween
and blotted with primary antibodies (see Supplemental Table 6.1) overnight at 4 ◦C.
After washing with 5% milk in TBS plus 0.1% tween, secondary antibody was applied
for one hour using donkey anti-mouse 790, donkey anti-mouse 680, or donkey anti-
rabbit 790 (Jackson ImmunoResearch, West Grove, PA). Blots were washed with TBS
and imaged using the Li-COR Odyssey CLx imaging system (LI-COR Biosciences,
Lincoln, NE). ERK1/2 served as a loading control. To generate a normalized fluo-
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rescence value, fluorescence intensity for each protein of interest at each time point
was normalized to its corresponding ERK1/2 loading control factor. The normalized
fluorescence value was divided by the +2 week normalized value to obtain the relative
fluorescence intensity for each time point.
4.2.8 Electrophysiological recordings
Whole cell patch clamp recordings were made at room temperature (21 ◦C) us-
ing HEKA EPC 10 amplifier and Patchmaster data acquisition software (HEKA,
Lambrecht/ Pfalz, Germany). Recording pipettes with the tip resistance of 4-7 MΩ
were fabricated from borosilicate capillary glass (1.2-mm outer diameter, 0.60-mm
inner diameter; Sutter Instrument Co., Novato, CA) using a P-1000 puller (Sutter
Instrument Co.,). The bathing solution contained (in mM): NaCl 140, MgCl2 1, KCl
5, CaCl2, HEPES 10, Glucose 10, pH7.3 (adjusted with NaOH). For current-clamp
recordings, pipettes were filled with internal solution containing (in mM): KCL 140,
MgCl2 5, CaCl2 2.5, EGTA 5, HEPES 10, pH 7.3 (adjusted with KOH) and for
voltage-clamp recordings, the internal solution contained (in mM): CsF 130, NaCl
10, HEPES 10, CsEGTA (EGTA in CsOH) 1. Inward sodium currents were recorded
in the voltage-clamp mode with the holding potential of -80 mV. Spontaneous action
potential activity was recorded in current-clamp mode without any current injection,
using 3 sweeps of 1 min each starting from the holding potential of -80 mV. RMP
was recorded in current-clamp mode at 0 pA immediately after establishing whole-
cell configuration. For evoked action potentials, the cells were allowed to stabilize in
the whole-cell configuration for 2 min before initiating ramp current injection with
depolarization from 0 to 40 pA for 1s. Action potential threshold was estimated from
ramp current injection. In addition to ramp depolarization, AP threshold was also
determined from 500 ms step current injections at RMP, with increments of 10pA
AP threshold, using dV/dt method. AP amplitude was measured as the height of
the peak from threshold and duration was measured as the width at the threshold.
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Fig. 4.1. Purification and quantification of MACS purified RGCS.
BRN3-tdTomato-Thy1.2 lines were immunopurified using expression
of Thy1.2. Purified hPSC-derived RGCs were plated on laminin or in
the presence of hPSC-derived astrocytes (A). Quantification revealed
66.87% ± 1.51% purified population of hPSC-derived RGCs (B). A
Students t-test was used to compare conditions, n=5 and significant
differences indicated as ****<0.0001. Error bars represent s.e.m.
When necessary, a small bias current was injected to maintain a similar baseline mem-
brane potential (near -70 mV) before depolarizing current injections. Spontaneous
postsynaptic currents were measured in the voltage-clamp mode at -80mV.
4.3 Results
4.3.1 Characterization of hPSC-derived RGCs
To date, studies have demonstrated that hPSC-derived RGCs posses voltage gated
sodium and potassium currents ranging from 1pA to 2nA [13, 20, 21, 25, 26], are re-
sponsive to glutamate [21], and can fire spontaneous action potentials [13,21]. While
many of these characteristics are indicative of developing neurons, the ability to derive
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hPSC-RGCs that possess a variety of mature phenotypic and functional features has
eluded researchers to date. Mature in vivo RGCs across many species demonstrate a
full complement of characteristics including large cell body sizes ranging from 70µm2
to 400µm2 [18, 172], complex neurite outgrowths [173], repetitive spontaneous fir-
ing [170], a RMP between -55 and -60 mV [126,169], large amplitude/high frequency
APs [169, 170], and nA of voltage gated currents [126, 170]. As such, experiments
were undertaken to elucidate the time course of hPSC-derived RGC maturation to
determine the onset of phenotypic and functional features in short (< 2 weeks) and
long term culture (>2 weeks).
BRN3-tdTomato-Thy1.2 reporter lines were differentiated using a stepwise pro-
tocol as previously described [10, 12, 13, 50]. hPSC-derived RGCs appeared around
day 45 of differentiation, at which time they were purified by magnetic activated cell
sorting (MACS) using expression of Thy1.2 on the cell surface of RGCs (Figure 4.1A).
This resulted in a 66.87%±1.51% purified population of hPSC-derived RGCs (Fig-
ure 4.1B). The resultant cells were plated on a laminin substrate to observe neurite
outgrowth in short term culture.
10 days post-plating, hPSC-derived RGCs displayed features of developing neu-
rons, including robust and complex neurite outgrowth (Figure 4.2 A-D). Soma size
increased from 46.63µm2 to 98.24µm2 in 10 days (Figure 4.2E) and RGC neurites grew
significantly in length, extending 142.51µm on average (Figure 4.2F). During short
term culture, the number of primary, secondary, tertiary and quaternary neurites
more than doubled (Figure 4.2G). RGC neurites also displayed a 662.8% increase in
the number of branch points over this time period (Figure 4.2H). These data indicated
that in short term culture, RGCs generated increasingly complex neurite outgrowths
as observed in vivo.
In addition to morphological maturation, hPSC-derived RGCs were character-
ized further for their electrophysiological maturation over a 4-week time course after
plating on laminin. Voltage-clamp recordings from hPSC-derived RGCs exhibited
an increase in peak sodium conductance as neurons matured from week 1 to week
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Fig. 4.2. hPSC-derived RGCs developed complex neurites in short
term culture.
Immunocytochemistry and representative tracings of hPSC-derived
RGCs demonstrated emerging complex morphologies over 10 days
post-plating (A-D). Cell body size increased from 46.63µm2 to
98.24µm2 (E). RGC neurites extended an average of 142.2µm in 10
days (F). Neurites of RGCs grew increasingly complex as indicated by
the significant increase in the number of primary, secondary, tertiary
and quaternary neurites (G) and number of branch points (H). One-
way ANOVA was used to compare timepoints, n=5 and significant
differences indicated as *<0.05, ** <0.01, ***<0.001, ****<0.0001.
Error bars represent s.e.m.
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4 post-plating (Figure 4.3A, B), with an average conductance of - 0.38 ± 0.03 nA
(n=10) at week 1; at week 2 = - 0.81 ±0.04 nA (n=8); at week 3 = -1.15 ± 0.03 nA
(n=6) and at week 4 = -1.48 ± 0.06 nA (n=9). Currents were elicited using a series
of depolarizations from the holding potential of -80 mV (Figure 4.3B, inset). There
was a significant hyperpolarized shift in V0.5 of activation (at week 1: V0.5 = 20.9 ±
1.3 mV, n=5; at week 2: V0.5 = 29.9 ± 0.9 mV, n=5; at week 3: V0.5 = 31.4 ± 1.6
mV, n=5 and at week 4: V0.5= 35.6 ± 0.9 mV, n=5) (Figure 4.3C) which signified
functional maturation of hPSC-derived RGCs. Current density plots displayed an
increase in sodium current, (week 1= -61.6 ±4.9 pA/pF, n=6; week 2= -136.7 ±7.1
pA/pF, n=4; week 3= -196.1 ±21.1 pA/pF, n=5 and week 4= -236.0± 20.8 pA/pF;
n=6) demonstrating an increase in the expression of voltage-gated sodium channels
as RGCs matured (Figure 4.3D). For the calculation of sodium current densities,
steady-state inactivation protocol was used to estimate peak sodium conductance to
minimize voltage-clamp errors.
hPSC-derived RGCs demonstrated the ability to fire spontaneous action potentials
as early as 2 weeks post-plating and by 4 weeks post-plating, trains of spontaneous
action potentials emerged (Figure 4.4A). By the end of 4 weeks post-plating, approx-
imately 37% of RGCs measured could fire spontaneous APs (Figure 4.4B). hPSC-
derived RGCs maintained a resting membrane potential of about -35.14±1.34mV and
no significant changes were observed throughout long term culture (Figure 4.4C).
To determine if hPSC-derived RGCs were forming presumptive synaptic connec-
tions, the presence of pre- and postsynaptic proteins was analyzed at 2, 4, and 6
weeks post-plating. hPSC-derived RGCs demonstrated increasing levels of the presy-
naptic protein SV2 by immunocytochemistry (Figure 4.5A). Western blot revealed
a potential trend of increasing presynaptic protein levels as indicated by Neurexin 1
(NRXN1) and Synapsin 1 (SYN1) (Figure 4.5B-C). Levels of the postsynaptic marker
PSD95 remained relatively stable. Taken together, these data indicate the formation
of presumptive synaptic connections in culture.
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Fig. 4.3. hPSC-derived RGCs demonstrated increasingly mature func-
tional characteristics in long term culture.
Patch clamp revealed an increase of inward voltage gated sodium cur-
rents from 400pA to 1.48nA over 4 weeks of plating (A). IV-curve dis-
played an increase in inward currents as RGCs matured (B). Voltage
dependence of activation indicated a significant shift in the hyperpo-
larized direction with the progression of RGCs from week 1 to week
4 post-plating(C). Current density plot demonstrated an increase in
sodium currents over 4 weeks, (week 1= -61.6 ± 4.9 pA/pF, n=6;
week 2= -136.7 ± 7.1 pA/pF, n=4; week 3= -196.1 ± 21.1 pA/pF,
n=5 and week 4= -236.0± 20.8 pA/pF; n=6) indicating an increase
in the expression of voltage-gated sodium channels with RGC matu-
ration (D). Significant differences indicated as *<0.05, ****<0.0001.
Error bars represent s.e.m.
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Fig. 4.4. hPSC-derived RGCs exhibited the ability to fire spontaneous
action potentials in long term culture.
RGCs demonstrated an increase in the ability to fire spontaneous
APs when analyzed by patch clamp over 4 weeks post-plating
(Vhold=-80mV) (A-B). hPSC-derived RGCs maintained a RMP of
-35.14±1.34mV (n=7) and no significant changes were observed
throughout long term culture (C). Error bars represent s.e.m.
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4.3.2 Enhanced phenotypic and functional maturation of hPSC-derived
RGCs co-cultured with hPSC-derived astrocytes
During short and long term culture, hPSC-derived RGCs generated complex neu-
rites, cell body sizes up to 98.24µm2, spontaneous action potentials and presumptive
synaptic connections. Astrocytes are known to modulate CNS maturation and pre-
vious studies have demonstrated the capacity for astrocytes to influence the synap-
tic development of neurons in culture [184–186]. As such, astrocyte co-culture was
employed as a strategy to enhance phenotypic and functional maturation of hPSC-
derived RGCs.
Multiple lines of hPSCs were differentiated to astrocytes following previously es-
tablished protocols [182, 183], leading to a 88.26±2.13% pure population of mature
hPSC-derived astrocytes after 9 months of differentiation (Figure 4.6). Mature astro-
cytes were co-cultured with immunopanned RGCs at 45 days of differentiation. Co-
cultures were grown in short and long term culture to observe changes in phenotypic
and functional development. Co-cultures were compared to control hPSC-derived
RGCs grown on laminin or in the presence of ACM.
10 days post-plating, RGCs maintained on laminin displayed robust neurite out-
growth, which significantly increased when these cells were co-cultured on astrocytes
(Figure 4.7 A-C). Astrocyte co-culture led to a 25% increase in RGC soma sizes
(Figure 4.7D) and over 200% longer neurites (Figure 4.7E). RGCs co-cultured with
astrocytes displayed significantly complex neurite outgrowths, demonstrated by the
increase in number of primary, secondary, tertiary and quaternary neurites (Figure
4.7F) as well as increased neurite branching (Figure 4.7G). ACM generated no signifi-
cant differences in soma size, neurite outgrowth, and complexity compared to control
conditions, indicating the effect of astrocytes on hPSC-derived RGCs was primarily
contact mediated.
Electrophysiological analysis was conducted on hPSC-derived RGCs grown on
laminin or co-cultured with hPSC-derived astrocytes at 3 weeks post-plating. APs
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were evoked using ramp current injection with depolarization from 0-40 pA (Vhold =
-80 mV) (Figure 4.8A). Co-cultured RGCs demonstrated an increased AP amplitude
(Figure 4.8B) as well as significantly increased numbers of APs (Figure 4.8C) that
correlated with a significant decrease in AP duration(Figure 4.8D) when compared
to laminin control. The resting membrane potential of these cells remained relatively
stable, averaging -35.25±0.92 mV regardless of culture condition (Figure 4.8E).
Taken together, these results indicated that co-culture with astrocytes enhanced
hPSC-derived RGC phenotypic complexity and functional maturation compared to
control and ACM conditions. RGCs co-cultured with astrocytes generated RGCs
more closely resembling mature in vivo RGCs. Co-cultured RGCs displayed soma
sizes around 119.2µm2, complex neurites reaching 862.7µm, as well as nanoamps of
voltage gated currents and large amplitude, high frequency trains of APs.
4.4 Discussion
The primary function of retinal ganglion cells is to transfer information from the
retina to the proper synaptic targets in the brain through the firing and propagation
of action potentials [187]. While electrical activity is vital to the function of adult
RGCs, electrical activity within the context of neural development is imperative for
cell survival, synaptic pruning, and the formation of phenotypic and functional char-
acteristics [170, 188–190]. However, the mechanisms that underlie RGC maturation
are not well understood, particularly within human RGCs. The ability to generate
populations of hPSC-derived RGCs has greatly expanded our knowledge of human
development and revolutionized the ability to produce novel therapies for patients
with optic neuropathies. However, optic neuropathies involve degeneration of ma-
ture RGCs that express a full complement of electrophysiological and phenotypic
features [191]. Thus, hPSC-derived RGCs must be able to mirror these features to
serve as physiologically-relevant models for translational applications.
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Fig. 4.5. hPSC-derived RGCs formed presumptive pre- and postsy-
naptic connections in long term culture.
hPSC-derived RGCs exhibited increasing expression of the presynap-
tic marker SV2 by immunocytochemistry (A). Western blot revealed
the presence of additional presynaptic markers including Neurexin-1
(NRXN1), Synapsin-1 (SYN1), and the postsynaptic marker PSD95
(B). ERK1/2 served as the loading control and relative fluorescence
intensity was calculated relative to the +2 week sample as described
in the methods (C).
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Fig. 4.6. Purification and quantification of hPSC-derived astrocytes.
Astrocytes demonstrated a typical star-like morphology under bright
field microscopy after nine months of differentiation (A). Immunocyto-
chemistry revealed robust expression of the mature astrocyte marker
GFAP (B), co-localized with other astrocyte associated markers (C-
F). Quantification of these markers indicated that 88.26% ± 2.13% of
DAPI positive cells in culture expressed astrocyte markers, resulting
in a highly pure population of hPSC-derived astrocytes (G). Error
bars represent s.e.m.
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The data presented in this manuscript demonstrates the ability to derive function-
ally active retinal ganglion cells with complex morphologies. Although mature in vivo
RGCs exhibit a full complement of phenotypic and electrophysiological features, it is
unclear to what extent hPSC-derived RGCs can mimic these characteristics. hPSC-
derived RGCs were studied in short term culture to observe the generation of synap-
tic complexity. hPSC-derived RGCs displayed large cell body sizes up to 98.24µm2.
These cells also developed numerous complex and lengthy neurites over the course
of short term culture. However, when hPSC-derived RGCs were co-cultured with
hPSC-derived astrocytes, the onset of these features appeared more rapidly. 10 days
post-plating, RGCs co-cultured with astrocytes displayed an average cell body size of
119.2µm2 and developed a greater number of complex primary neurites compared to
control RGCs. While control RGCs developed neurites reaching 244.4µm, co-cultured
RGC neurites extended distances of up to 850.1µm in ten days.
hPSC-derived RGCs were maintained in long term culture to monitor the onset of
electrophysiological features. To date, groups have demonstrated that hPSC-derived
RGCs conduct sodium and potassium currents [13,20,21,25,26], and have the ability
to fire APs [13,20,21,25,26,168]. However, very little is known about when these fea-
tures emerge and to what extent hPSC-derived RGCs can develop mature functional
characteristics. Nascent in vivo RGCs generate spontaneous activity early in develop-
ment [170]. Spontaneous activity is important for refining early retinal circuitry and
shaping the physiological development of mature RGCs [170,188–190]. As RGCs be-
gin to mature, they develop intrinsic membrane properties such as large voltage gated
currents [126,169,170], a hyperpolarized RMP [126,169,171], the ability to fire trains
of APs [126,170], and cell body sizes ranging from 70µm2 to 400µm2 [18,172]. Sodium
and potassium channel development have been shown across numerous studies to play
a crucial role in maintenance of retinal circuitry [126,169–171]. During development,
the ability of RGCs to regulate their ion channel kinetics is directly related to the
ability of these cells to fire action potentials in response to stimulation [126,170,192].
As RGCs increase the ability to conduct sodium and potassium currents, the ability
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to fire large amplitude, short half-width action potentials increases. In the pres-
ence of astrocytes, hPSC-derived RGCs generated trains of action potentials when
stimulated compared to very little activity generated from control RGCs. Astro-
cytes promoted AP maturation as evidenced by an increase in the AP amplitude
with a corresponding decrease in AP duration (width at threshold) which mirrors
neuronal maturation in vivo. These data taken together indicate that hPSC-derived
astrocytes significantly enhanced hPSC-derived RGC phenotypic and functional mat-
uration. Previous groups have investigated RGC maturation in co-cultured rodent
RGCs with rodent astrocytes due to limited availability of human samples [184,186].
However, the experiments outlined in this manuscript are the first to utilize hPSCs to
explore in depth maturation of human retinal ganglion cells and the effect of human
astrocytes upon this process.
One result that proved confounding was the minor changes observed in the rest-
ing membrane potentials of these cells in long term culture. The average rest-
ing membrane potential of an mature RGC across most species is around -56.1±
7.8mv [126,170,171]. Despite long term culture with astrocytes, hPSC-derived RGCs
demonstrated an average RMP of -35.14 mV with no significant changes during long
term culture regardless of culture condition. Other studies exploring the development
of electrophysiological characteristics in stem cell-derived neurons have reported sim-
ilar findings. hPSC-derived neurons grown in long term culture displayed a RMP
between -35mV and -50mV [185, 193–196]. The inability of RGCs to develop a ma-
ture RMP is likely due to limitations of the cell culture environment. Although
culture conditions for RGC differentiation have been optimized, the synthetic in vitro
environment is inherently different from the in vivo environment where RGCs ma-
ture naturally. Exploring ways to provide hPSC-derived RGCs with an in vivo-like
environment might improve RMP. For instance, because neural circuitry develop-
ment is dependent upon input into the system, external stimulation of RGCs might
provide the exogenous activity necessary to push hPSC-derived RGCs to a more ma-
ture state [170, 188–190]. Moreover, the in vivo optic nerve is characterized by the
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Fig. 4.7. hPSC-derived astrocytes enhanced phenotypic development
of hPSC-derived RGCs.
10 days post-plating, RGCs co-cultured with astrocytes exhibited in-
creased complex neurite morphologies compared to laminin control
and ACM conditions as seen by immunocytochemistry and represen-
tative tracings (A-C). Astrocyte co-culture led to a significant increase
in RGC soma size from an average of 95.21µm2 in control and ACM
conditions to an average of 119.22µm2 in co-culture(D). hPSC-derived
RGCs cultured with astrocytes also exhibited increased neurite length
(E) and enhanced synaptic complexity(F). RGCs grown with astro-
cytes displayed an increase in neurite branching compared to control
and ACM conditions (G). One-way ANOVA was used to compare con-
ditions, n=5 and significant differences indicated as *<0.05, ** <0.01,
***<0.001, ****<0.0001. Error bars represent s.e.m.
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presence of other cell types, including oligodendrocytes which form insulating myelin
sheaths [197, 198]. Previous work has demonstrated that co-culturing rodent RGCs
with oligodendrocyte progenitor cells (OPCs) can generate myelin sheaths surround-
ing RGC axons [199]. Interestingly, the presence of astrocytes in this study promoted
rapid myelination of RGC axons in OPC co-culture. Future studies should be con-
ducted exploring the role of OPC co-culture in hPSC-dervied RGC development.
Lastly, perhaps -35mV is the maximum RMP hPSC-derived RGCs can attain in cul-
ture. If this is the case, RMP is established during the first week of plating, much
earlier in hPSC-derived RGC development than anticipated. Future work should be
done to elucidate the exact developmental timing of RMP onset.
Astrocytes play an essential and often underappreciated role within the central
nervous system. It is becoming increasingly clear that astrocytes are not passive
participants in neural development, but play instructive roles in shaping phenotypic
and functional maturation [181,200,201]. Within the retina, astrocytes and RGCs lie
closely associated in the nerve fiber layer and optic nerve [202]. Previous work has
established that astrocytes play a critical role in the formation of tripartite synapses
which contain the pre- and postsynaptic membrane closely associated with an as-
trocyte [200, 201, 203–205]. In fact, recent studies have shown one astrocyte can
associate with multiple neurons and can have wide reaching effects on up to 100,000
synapses [204,206,207].
In the current study, hPSC-derived astrocytes demonstrated effects on hPSC-
derived RGC maturation primarily through contact mediated signaling. hPSC-derived
RGCs grown in direct contact with astrocytes displayed a significant increase in neu-
rite length and complexity. In addition, astrocytes enhanced hPSC-derived RGC
functional properties by increasing the frequency of APs and generating large ampli-
tude, short half width APs. Previous studies have uncovered that direct contact of
neurons and astrocytes can increase functional activity of developing neurons, lead-
ing to larger voltage gated currents and expedited AP maturation [201, 206, 208].
Although paracrine mediated signaling has been shown to play a role in RGC mat-
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Fig. 4.8. hPSC-derived astrocytes enhanced functional maturation of
hPSC-derived RGCs.
Representative traces of AP firing recorded from hPSCs-derived RGCs
grown without and with astrocytes 3 weeks post-plating. APs were
evoked using ramp current injection with depolarization from 0-40 pA
(Vhold = -80 mV) (A). Summarized data for AP maturation demon-
strated that AP amplitude (B) and AP firing (C) increased signifi-
cantly and correlated with a significant decrease in AP duration (D)
for RGCs co-cultured with astrocytes. Regardless of culture condi-
tions, the resting membrane potential of remained relatively stable
across at approximately -35mV (n=8) (E). Significant differences in-
dicated as ** p=0.005; **** p<0.0001. Error bars represent s.e.m.
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uration, numerous studies have indicated that soluble factors secreted by astrocytes
might be more important in the generation of inhibitory and excitatory synapses and
maintenance of these synapses, [201, 206, 209, 210] which was not quantified in this
study. However, it is important to note that previous work has suggested that direct
contact of RGCs and astrocytes is necessary for RGCs to respond to soluble factors
released from astrocytes [201, 208]. Without this initial contact, ACM may not have
the capacity to influence hPSC-derived RGCs. Future work should be carried out to
determine to what extent hPSC-derived RGCs can respond to soluble factors released
from astrocytes.
Given the influence of astrocytes in the CNS, it would also be useful to understand
the role astrocytes play in the disease process. While astrocytes are typically thought
to exert a positive influence on the nervous system, their effects can be detrimental
if they become reactive when injured or diseased [211–214]. Experiments aimed at
uncovering the interplay between diseased astrocytes and healthy RGCs would aid in
understanding the mechanisms underlying optic neuropathies and present additional
therapeutic targets. Groundbreaking studies from the field of amyotrophic lateral
sclerosis (ALS) have shown that diseased astrocytes can negatively impact healthy
neurons [213,215]. hPSC-astrocytes derived from patients with genetic and sporadic
forms of ALS were co-cultured with hPSC-derived motor neurons from healthy, non-
ALS subjects. Both populations of diseased astrocytes were similarly toxic to motor
neurons, indicating a non-cell autonomous contribution of astrocytes to the disease
process [213]. Conversely, healthy hPSC-derived astrocytes have been shown to confer
some degree of protection to hPSC-derived motor neurons derived from ALS patients
[216–218]. Future studies should explore the role of astrocytes in the onset and
development of optic neuropathies.
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4.5 Conclusion
The data presented here demonstrates that hPSC-derived RGCs mirror many
of the phenotypic and functional features of in vivo RGCs. Furthermore, the clear
contribution of astrocytes to enhanced RGC maturity are in close agreement with
previous data suggesting the importance of astrocytes in RGC maturation. The
finding that hPSC-derived RGCs can recapitulate many features of in vivo RGCs will
contribute to the overall goal of developing efficacious therapies for patients suffering
from optic neuropathies.
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5. DISCUSSION
Human pluripotent stem cells possess the remarkable ability to self renew and dif-
ferentiate into virtually any cell type of the body [5, 6]. This makes hPSCs powerful
tools for novel translational applications. hPSCs allow for investigation into some of
the earliest time points in human embryonic development. The generation of human
cell lines allows for the development of models that reveal mechanisms of human dis-
ease, thereby bridging the gap in the translation of therapies from animal models to
human patients. hPSCs also allow for the generation of millions of patient specific
cells for cell replacement therapy and high-throughput drug screening.
The retina is an ideal place to study translational applications of hPSCs because
it is can be manipulated easily. It can be monitored using non-invasive techniques,
which is difficult for other locations in the brain and spinal cord. Its structure is also
well characterized, containing defined neuronal types. Although the retina is small
in size, the visual system accounts for approximately 80% of the sensory information
that is processed by the brain [219,220].
Many protocols have been developed to generate retinal neurons from hPSCs,
primarily based on information gathered from developmental studies in animal models
and the limited data obtained from postmortem human retinal tissues [8–13, 21, 53].
It is well established that retinal development occurs in a stepwise manner through
the interplay of different signaling pathways that instruct retinal generation in a
chronological and stepwise fashion [7]. The retina begins as two outgrowths from the
early neural tube. These outgrowths invaginte to form optic cup structures, which
eventually develop into stratified retinal tissue.
Many hPSC differentiation protocols seek to mimic in vivo development in a cell
culture environment by exogenously activating the proper signaling pathways using
expensive growth factors and small molecules [8,21,26,54,221]. However, the protocol
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developed by the Meyer Lab relies on the ability of hPSCs to intrinsically differentiate
towards a neural lineage in the absence of extrinsic signaling, also called default
differentiation [10,53,222]. This default differentiation protocol generates populations
of optic vesicle-like structures, which are >95% enriched for CHX10 expressing retinal
progenitor cells. Optic vesicles give rise to retinal organoids, which recapitulate the
spatial and temporal organization of an in vivo retina [9, 30]. Retinal ganglion cells
are specified first, followed shortly by cone photoreceptors and amacrine cells, while
later-born cell types such as rods and Muller glia arise near the end of organoid
development. Furthermore, retinal ganglion cells develop on the inner layers of retinal
organoids, while photoreceptors emerge along the outer layers.
However, the development and characterization of RGCs had been relatively ig-
nored in the field of hPSC retinal cell biology because of difficulties in cell type
identification. Due to the limited availability of specific markers for RGCs, studies
instead focused on the generation of RPE and photoreceptors, cell types residing in
the outer retina [100,223]. These cells have a unique morphology and exhibit specific
genetic markers to identify them from a pluripotent source. As such, the study of
disorders affecting the outer retina- such as AMD- were the initial focus of efforts in
the field while studies of inner retinal disorders and subsequently affected cell types
(such as RGCs) lagged behind.
Thus, efforts in the lab prioritized the definitive identification of retinal ganglion
cells from a pluripotent source. One of the most reliable markers of RGCs is BRN3,
which is also found in somatosensory and auditory neurons [36, 37, 39, 40]. Lack of
specificity complicated efforts to assign an identity to a BRN3 positive cell differenti-
ated from hPSCs. However, the ability to generate and isolate purified organoids that
contained a highly enriched population of retinal progenitor cells allowed BRN3 to be
used as a definitive marker of RGCs. Once a cell has become specified as a CHX10-
positive retinal progenitor, it is locked into its retinal fate and cannot differentiate
into anything other than a retinal neuron [32]. Extensive characterization using the
Meyer protocol demonstrated that BRN3 was expressed in conjunction with other
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RGC-associated markers [10,13,13,50,53,80,167]. Analyzing the spatial organization
of human retinal organoids, BRN3 was found restricted to the inner layers, further
confirming its use as a marker for RGCs.
As in vivo retinal ganglion cells develop, they extend neurites into the environment
to explore their surroundings. As these cells begin to make rudimentary connections
with neighboring neurons, RGC neurites will undergo compartmentalization, includ-
ing development of a defined axon, multiple dendrites and the soma [224]. Compart-
mentalization is imperative for the proper physiological function of a neuron. RGC
dendrites receive input from retinal interneurons and pass this information to the
brain in the form of APs that propagate along their axons [187]. The axons of RGCs
bundle together in the nerve fiber layer to form the optic nerve, which travels into
the brain to synapse with the LGN or SC.
hPSC-derived RGCs recapitulated many in vivo features, including the generation
of many neurites that eventually compartmentalized into a polarized neuron with
multiple dendrites, a soma and a single axon [13]. hPSC-derived RGC axons exhibited
the capacity to fasciculate in an optic-nerve like manner and extended distances of
up to 1.5mm in a 24 hour period. In addition, these cells possessed the ability
to fire APs [20, 21, 25, 26], maintained a hyperpolarized RMP [13], and conducted
ions through voltage gated channels [13, 20, 25, 26]. Although hPSC-derived RGCs
lacked features of a bona fide optic nerve, such as oligodendrocytes, astrocytes and
vasculature, the ability of these cells to mirror the basic structure and function of in
vivo RGCs is remarkable.
After successful generation and characterization of hPSC-derived RGCs, these
cells were used to establish a model for glaucoma [13]. Glaucoma can be divided
into two broad categories, primary open angle glaucoma and closed angle glaucoma
(CAG) [166,225]. POAG is the most common form of the disorder and is traditionally
associated with an elevated intraocular pressure [58,166,225]. However, elevated IOP
is no longer a defining characteristic of POAG [59, 166, 226], although it remains a
risk factor for the disease. In fact, normal IOP has been observed in up to 50% of
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POAG patients [3, 57, 227]. As such, glaucoma has recently been recharacterized as
a disorder that causes slow and progressive loss of RGCs via apoptosis, leading to
deficits in the visual field [159,166,225].
Although the mechanism underlying RGC degeneration has not been uncovered,
recent studies suggest that axonal transport in RGCs is perturbed in POAG [161,
189, 228]. Axonal transport is critical to RGC survival due to the neuroprotective
signals these cells receive from their synaptic targets. Muller glia endfeet are closely
associated with the ganglion cell layer and have been shown to provide CNTF, PEDF,
GDNF, and BDNF to RGCs [157,158,162,229] while synaptic targets in the brain such
as the LGN supply BDNF, NGF, and NT4/5 retrogradely to RGCs [162–165]. Re-
cent studies have suggested that blockage of axonal transport due to injury obstructs
signaling of neuroprotective factors [161, 228, 230, 231]. Once signaling cascades are
blocked, the ganglion cells are triggered to self destruct through apoptosis [166,232].
Supplementing animals with BDNF has shown to rescue retinal ganglion cells in
rodent glaucoma models [159, 160, 233]. Interestingly, this same mechanism is remi-
niscent of early development, wherein RGCs that fail to reach the proper target in
the brain do not receive this protective signaling and degenerate [161,234,235].
It is hypothesized that the mechanism of degeneration is similar across all forms
of glaucoma, even if the inciting event that causes the damage varies from person to
person [166,226]. As such, a glaucoma model does not necessarily need to recreate the
initial stressor that induces damage, but instead should recapitulate the primary phe-
notype observed- specifically a targeted loss of RGCs by apoptosis. As such, we aimed
to establish a genetic model of glaucoma using fibroblasts obtained from a patient
with an E50K mutation in the OPTN gene, causative for normal tension POAG [131].
E50K mutations in OPTN are relatively rare, occurring in approximately 3-13% of
patients with POAG [236, 237]. However, investigating the mechanism of RGC de-
generation in E50K hPSC-derived RGCs might have wide-ranging implications for all
forms of POAG, serve as a complement to existing animal models and help narrow
the gap in generating translational therapies.
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E50K patient-derived RGCs displayed increased apoptosis compared to control
hPSC-derived RGCs. Interestingly, apoptosis in E50K RGCs was diminished with
the treatment of neuroprotective factors BDNF and PEDF. In vivo RGCs receive
BDNF from the LGN and PEDF from Muller glia [157, 161, 162]. These results
support the importance of neuroprotective signaling in disease states and displayed
a proof of principle that E50K RGCs could serve as a platform for high-throughput
drug screening in future studies. Although it is clear that this model recapitulates
apoptotic cell death of RGCs, the precise interplay of OPTN in glaucoma is still
unknown. OPTN is an autophagy receptor and it is hypothesized that autophagy
dysregulation plays a role in many forms of neurodegeneration [238,239].
While treatment of E50K RGCs with neuroprotective factors appeared to reduce
apoptosis, neuroprotective therapies remain difficult to translate to patients. These
proteins have a half-life of approximately 10 minutes in the circulatory system, mean-
ing that systemic delivery is not an optimal route of administration [240,241]. More-
over, the blood-retina barrier functions in much the same way as the blood-brain bar-
rier, presenting further obstacles to effective systemic drug delivery. Although the eye
is relatively easy to access via intravitreal injections, sustained delivery of neuropro-
tective factors in this way is simply unrealistic. Studies have explored the possibility
of engineering astrocytes to express high levels of neuroprotective factors [242–244].
Engineered astrocytes can be transplanted into the retina and serve as a local source
of these proteins. Other strategies include the use of gene therapy to express neuro-
protective factors in RGCs or Muller glia [245, 246]. Combinations of gene therapy
and cell mediated delivery of neuroprotective factors have shown promising results
in animal models [240, 247]. It is unknown how well these therapies will translate to
human patients.
Furthermore, hPSC models contain their own set of limitations. hPSCs allow for
generation and the straightforward analysis of one human cell type in a dish. However,
differentiated cells exist outside the ecosystem of a tissue or organism. While hPSCs
may help determine what drugs are efficacious for specific cell types, it is difficult
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to determine side effects or elucidate the complex pharmacokinetics of compounds
without a whole organism.
However, it must be noted that adult RGCs degenerate in optic neuropathies.
Therefore, to serve as a more physiologically relevant model, hPSC-derived RGCs
should replicate the phenotypic and functional features of mature, in vivo RGCs. As
such, methods were explored to improve the E50K disease model by investigating the
capacity of hPSC-derived RGCs to become phenotypically and functionally mature.
Preliminary evidence suggested that prolonged culture of hPSC-derived RGCs gener-
ated neurons that could fire single APs [13, 20, 21, 25, 26], maintain a hyperpolarized
RMP of about -35mV [13] and conduct picoamps of current through voltage gated
channels [13, 20, 25, 26]. However, these features were typical signs of an immature
RGC. Mature mammalian RGCs have the capacity to fire trains of APs in response
to stimuli [126, 170], maintain a RMP between -55 and -60mV [126, 169, 171], and
develop complex and lengthy neurites that eventually form pre- and postsynaptic
connections [173]. As such, methods were explored to generate mature hPSC-derived
RGCs. Approaches included optimizing cell culture conditions and exploring the role
of astrocytes to enhance RGC maturation.
Astrocytes play an underappreciated role within the nervous system. It is be-
coming increasingly clear that astrocytes are not passive participants in neural de-
velopment, but play instructive roles in shaping phenotypic and functional matura-
tion [181, 200, 201]. hPSC-derived RGCs co-cultured with hPSC-derived astrocytes
displayed enhanced synaptic and electrophysiological maturation. These cells exhib-
ited nA of voltage gated currents, trains of action potentials in response to stimuli,
and complex neurite morphology. While astrocytes are typically thought to exert a
positive influence on the nervous system, their effects can be detrimental if they be-
come reactive when injured or diseased [211–214]. Recent studies have demonstrated
that when hPSC-astrocytes derived from patients with genetic and sporadic forms of
ALS were co-cultured with hPSC-derived motor neurons from healthy subjects, both
populations of diseased astrocytes were similarly toxic to motor neurons [213]. These
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data indicate a non-cell autonomous contribution of astrocytes to the disease process.
Conversely, healthy hPSC-derived astrocytes have been shown to confer some degree
of protection to hPSC-derived motor neurons derived from ALS patients [216–218].
Future experiments aimed at uncovering the interplay between diseased astrocytes
and healthy RGCs are the next step in glaucoma disease modeling. Co-culturing
E50K astrocytes with wild type RGCs would help elucidate the non-cell autonomous
contributions of astrocytes to glaucoma. The establishment of healthy hPSC-derived
astrocytes co-cultured with E50K RGCs might confer some level of protection of
diseased RGCs and present additional therapeutic targets.
Drug screening platforms to identify neuroprotective agents and therapeutic tar-
gets are useful in early stages of neurodegeneration. However, once neurons in the
central nervous system are lost, they have no capacity for regeneration. Moreover, the
CNS has an extraordinary capacity for adaptation and as such, vision loss is usually
not evident in patients until 50% of the retinal ganglion cells are lost [3, 4, 58, 248].
Clinical screening for glaucoma can only detect gross changes to retinal architecture
that occur once a large population of the ganglion cells have irreversibly degener-
ated [166]. This necessitates the need for cell replacement therapies for patients who
have lost a significant portion of their RGCs to degeneration.
Cell replacement therapy requires the successful completion of numerous steps.
Transplanted neurons must first integrate to the proper position within the retina and
make presynaptic connections with appropriate cells, primarily amacrine and bipolar
cells. Once neurons have integrated into the ganglion cell layer, they must extend their
axons from the retina to the LGN, a distance of approximately 110mm in humans [19].
After hPSC-derived RGC axons traverse this distance, they must navigate to the
proper synaptic target in the brain and establish functional postsynaptic connections.
Integration into the retina is challenging due to retinal injury and immune re-
sponses, as well as missing developmental cues RGCs normally receive during neuro-
genesis and synaptogenesis. However, ongoing research suggests that hPSC-derived
neurons and RGCs display some capacity to integrate into rodent retinas [72–74,249],
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with approximately 3.2% of cells surviving one week after transplant [74, 249]. Reti-
nal progenitors and newly specified RGCs demonstrate greater capacity for survival
after transplant than adult RGCs. Interestingly, it appears that integration is more
successful in mouse models of RGC degeneration compared to healthy mice, although
the mechanisms underlying this phenomenon remain unknown. Furthermore, multi-
ple studies have demonstrated that less than 1% of integrated neurons can make the
journey from the RGC layer to the LGN and form synapses [73,74].
Recent studies have demonstrated that hPSC-derived RGCs possess the capacity
to respond to growth cues and and can travel up to 1.5mm in just 24 hours. In addi-
tion, hPSC-derived RGCs exhibit target specificity, preferentially targeting explants
of SC over non-target tissues such as the olfactory bulb [25]. Current work indicates
that hPSC-derived RGCs develop functional properties similar to those of in vivo
RGCs. Taken together, it is clear that hPSC-derived RGCs possess some capacity for
in vivo cell replacement. More research is needed to optimize the steps involved in
successful cell replacement therapy. Future experiments include exploring the expres-
sion of specific guidance receptors expressed by hPSC-derived RGCs throughout their
growth and development. Once the precise developmental timing of these receptors is
known, ways in which to guide RGC outgrowths to a target, such as a LGN explant,
should be explored. Lastly, once hPSC-derived RGCs synapse with an ex vivo target
tissue in vitro, the ability of RGCs to form functional synaptic connections can be
analyzed. Optogenetic stimulation of hPSC-derived RGCs and subsequent calcium
imaging of the target tissue would be one way to conduct such an experiment.
Another obstacle to development of successful therapies is the time, cost, and
labor needed to generate populations of hiPSCs for individual patients. One way
to overcome this challenge is to generate human leukocyte antigen (HLA) and ABO
blood group matched hiPSCs in combination with immunosuppressants. The same
methods are used to ensure successful organ transplants between individuals [250,251].
A recent study in the United Kingdom determined that the generation of 150 lines
98
from O negative donors of varying HLA types would be compatible for approximately
80% of the British population [252].
The eye is uniquely immune privileged. In fact, many corneal transplant recipients
often to do not undergo HLA matching, yet 90% of them are accepted with few
complications [253]. This does not mean that transplants into the eye suffer from no
rejection; only that immune rejection within the eye is significantly reduced. Recent
data suggests that transplanted retinal progenitor cells are likely to be rejected if they
cannot integrate and differentiate to the appropriate cell type [254,255]. However, the
transplant of differentiated retinal neurons experience little immune rejection [72].
5.0.1 Conclusion
Since the first description of hPSCs two decades ago, hPSC technology has ad-
vanced quickly. The work presented in this dissertation demonstrates the first in depth
characterization of RGCs from a pluripotent source, largely ignored in the field of reti-
nal stem cell biology. hPSC-derived RGCs exhibited the ability to generate lengthy
neurites and compartmentalize into RGCs with many functional characteristics. Us-
ing this knowledge, a glaucoma disease model was generated from a patient with
an E50K mutation in the OPTN gene, causative for POAG. Patient-derived RGCs
demonstrated an increase in apoptosis as observed across all forms of POAG. Treat-
ment with neuroprotective factors reduced cell death, indicating that diseased RGCs
could serve as a platform for high-throughput screening in future studies. However, to
serve as physiologically relevant models for translational applications, hPSC-derived
RGCs were assayed for their ability to mirror in vivo RGC phenotypic and functional
maturation, which could be greatly enhanced by the presence of hPSC-derived as-
trocytes. Taken together, these data contribute to the greater understanding of the
ways in which hPSC-derived RGCs could be used for drug screening, cell replacement
therapies, and disease modeling applications to enhance our knowledge of human
development and generate novel therapies for optic neuropathies.
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6. SUPPLEMENTAL TABLES
Table 6.1.: Primary antibodies used for immunocytochem-
istry and western blot
Antibody Source Catalog Number Dilution
Activated Caspase-3 Promega G748A 1:500
AFP Santa Cruz Biotechnology SC-15375 1:50
BIIITubulin Covance PRB-435P 1:100
BRN3 Santa Cruz Biotechnology SC-6026 1:50
Calretinin Millipore AB1550 1:500
CHX10 Santa Cruz Biotechnology SC-21690 1:200
CRX Abnova H00001406-M02 1:100
DLX5 Abcam Ab64827 1:200
EAAT1 Santa Cruz Biotechnology SC-515839 1:100
ERK1/2 Santa Cruz Biotechnology SC-514302 1:500
GFAP Cell Signaling Technology D1F4Q 1:200
GFAP Millipore MABA360 1:200
GM130 BD Pharmigen 560257 1:50
HuC/D Life Technologies A-21271 1:200
ISLET1
Developmental Studies
Hybridoma Bank
40.2D6 1:200
LHX2 Santa Cruz Biotechnology SC-19344 1:200
MAP2 Santa Cruz Biotechnology SC-20172 1:200
mGluR2 Millipore MAB397 1:500
MITF Exalpha X1405M 1:200
NANOG R&D Systems AF1997 1:100
Continued on next page.
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Table 6.1.: continued
Antibody Source Catalog Number Dilution
Nestin Santa Cruz Biotechnology SC-23927 1:10
Neurexin-1 Millipore ABN161-I 1:1000
OCT4 Stemgent 09-0023 1:200
OPN4 ThermoFisher PA1-781 1:500
OTX2 R&D Systems AF1979 1:2000
PAX6
Developmental Studies
Hybridoma Bank
PAX6 1:50
RBPMS PhosphoSolutions 1830-RBPMS 1:500
Recoverin Chemicon AB5585 1:2000
RFP Rockland 600-401-379 1:1500
S100β Abcam Ab11178 1:200
SIX6 Sigma-Aldrich HPA001403 1:200
SMA Millipore CBL171 1:100
SNAP25 Millipore MAB331 1:500
SOX1 R&D Systems AF3369 1:1000
SOX2 R&D Systems AF2018 1:1000
SSEA-4 Chemicon 09-0006 1:500
SV2
Developmental Studies
Hybridoma Bank
SV2A 1:1000
Synapsin-1 Calbiochem 574777 1:1000
TAU Santa Cruz Biotechnology SC-21796 1:50
Tra-1-60 Chemicon 09-0010 1:1000
Tra-1-81 Chemicon 09-0011 1:1000
Vimentin Santa Cruz Biotechnology SC-6260 1:100
ZO-1 Zymed 61-7300 1:100
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